<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care - Candy, B - 2022 | Cochrane Library</title> <meta content="Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care - Candy, B - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006332.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care - Candy, B - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006332.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006332.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care" name="citation_title"/> <meta content="Bridget Candy" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="b.candy@ucl.ac.uk" name="citation_author_email"/> <meta content="Louise Jones" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Victoria Vickerstaff" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Philip J Larkin" name="citation_author"/> <meta content="UCD College of Health Sciences" name="citation_author_institution"/> <meta content="Patrick Stone" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006332.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/09/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006332.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006332.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006332.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Opioid [adverse effects]; Naloxone; Naltrexone [analogs &amp; derivatives]; Narcotic Antagonists [adverse effects]; *Neoplasms [drug therapy]; *Opioid-Induced Constipation; Oxycodone; Palliative Care; Quaternary Ammonium Compounds; *Substance Withdrawal Syndrome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006332.pub4&amp;doi=10.1002/14651858.CD006332.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006332\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006332\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006332.pub4",title:"Mu\\u2010opioid antagonists for opioid\\u2010induced bowel dysfunction in people with cancer and people receiving palliative care",firstPublishedDate:"Sep 15, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006332.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006332.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006332.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006332.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006332.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006332.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006332.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006332.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006332.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006332.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3447 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006332.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/appendices#CD006332-sec-0145"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/supinfo/CD006332StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/supinfo/CD006332StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#CD006332-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Bridget Candy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#CD006332-cr-0005">Louise Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#CD006332-cr-0006">Victoria Vickerstaff</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#CD006332-cr-0007">Philip J Larkin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information#CD006332-cr-0008">Patrick Stone</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information/en#CD006332-sec-0157">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 September 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006332.pub4">https://doi.org/10.1002/14651858.CD006332.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006332-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006332-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006332-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006332-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006332-abs-0009">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006332-abs-0001" lang="en"> <section id="CD006332-sec-0001"> <h3 class="title" id="CD006332-sec-0001">Background</h3> <p>Opioid‐induced bowel dysfunction (OIBD) is characterised by constipation, incomplete evacuation, bloating, and gastric reflux. It is one of the major adverse events (AEs) of treatment for pain in cancer and palliative care, resulting in increased morbidity and reduced quality of life. </p> <p>This review is a partial update of a 2008 review, and critiques as previous update (2018) trials only for people with cancer and people receiving palliative care. </p> </section> <section id="CD006332-sec-0002"> <h3 class="title" id="CD006332-sec-0002">Objectives</h3> <p>To assess for OIBD in people with cancer and people receiving palliative care the effectiveness and safety of mu‐opioid antagonists (MOAs) versus different doses of MOAs, alternative pharmacological/non‐pharmacological interventions, placebo, or no treatment. </p> </section> <section id="CD006332-sec-0003"> <h3 class="title" id="CD006332-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science (December 2021), clinical trial registries and regulatory websites. We sought contact with MOA manufacturers for further data. </p> </section> <section id="CD006332-sec-0004"> <h3 class="title" id="CD006332-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) assessing the effectiveness and safety of MOAs for OIBD in people with cancer and people at a palliative stage irrespective of the type of terminal disease. </p> </section> <section id="CD006332-sec-0005"> <h3 class="title" id="CD006332-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed risk of bias and extracted data. The appropriateness of combining data from the trials depended upon sufficient homogeneity across trials. Our primary outcomes were laxation response, effect on analgesia, and AEs. We assessed the certainty of evidence using GRADE and created summary of findings tables. </p> </section> <section id="CD006332-sec-0006"> <h3 class="title" id="CD006332-sec-0006">Main results</h3> <p>We included 10 studies (two new trials) randomising in‐total 1343 adults with cancer irrespective of stage, or at palliative care stage of any disease. The MOAs were oral naldemedine and naloxone (alone or in combination with oxycodone), and subcutaneous methylnaltrexone. The trials compared MOAs with placebo, MOAs at different doses, or in combination with other drugs. Two trials of naldemedine and three of naloxone with oxycodone were in people with cancer irrespective of disease stage. The trial on naloxone alone was in people with advanced cancer. Four trials on methylnaltrexone were in palliative care where most participants had advanced cancer. All trials were vulnerable to biases; most commonly, blinding of the outcome assessor was not reported.  </p> <p><b>Oral naldemedine versus placebo</b> </p> <p>Risk (i.e. chance) of spontaneous laxations in the medium term (over two weeks) for naldemedine was over threefold greater risk ratio (RR) 2.00, 95% confidence interval (CI) 1.59 to 2.52, 2 trials, 418 participants, I² = 0%. Number needed to treat for an additional beneficial outcome (NNTB) 3, 95% CI 3 to 4; moderate‐certainty evidence). Earlier risk of spontaneous laxations and patient assessment of bowel change was not reported. Very low‐certainty evidence showed naldemedine had little to no effect on opioid withdrawal symptoms. There was little to no difference in the risk of serious (non‐fatal) AEs (RR 3.34, 95% CI 0.85 to 13.15: low‐certainty evidence). Over double the risk of AEs (non‐serious) reported with naldemedine (moderate‐certainty evidence). </p> <p><b>Low‐dose oral naldemedine versus higher dose</b> </p> <p>Risk of spontaneous laxations was lower for the lower dose (medium term, 0.1 mg versus 0.4 mg: RR 0.69, 95% CI 0.53 to 0.89, 1 trial, 111 participants (low‐certainty evidence)). Earlier risk of spontaneous laxations and patient assessment of bowel change not reported. Low‐certainty evidence showed little to no difference on opioid withdrawal symptoms (0.1 mg versus 0.4 mg mean difference (MD) ‐0.30, 95% CI ‐0.85 to 0.25), and occurrences of serious AEs (0.1 mg versus 0.4 mg RR 0.25, 95% CI 0.03 to 2.17). Low‐certainty evidence showed little to no difference on non‐serious AEs. </p> <p><b>Oral naloxone versus placebo</b> </p> <p>Risk of spontaneous laxations and AEs not reported. Little to no difference in pain intensity (very low‐certainty evidence). Full data not given. The trial reported that no serious AEs occurred. </p> <p><b>Oral naloxone + oxycodone versus oxycodone</b> </p> <p>Risk of spontaneous laxations within 24 hours and in the medium term not reported. Low‐certainty evidence showed naloxone with oxycodone reduced the risk of opioid withdrawal symptoms. There was little to no difference in the risk of serious (non‐fatal) AEs (RR 0.68, 95% CI 0.44 to 1.06), 3 trials, 362 participants, I² = 55%: very low‐certainty evidence). There was little to no difference in risk of AEs (low‐certainty evidence).  </p> <p><b>Subcutaneous methylnaltrexone versus placebo</b> </p> <p>Risk of spontaneous laxations within 24 hours with methylnaltrexone was fourfold greater than placebo (RR 2.97, 95% CI 2.13 to 4.13. 2 trials, 287 participants, I² = 31%. NNTB 3, 95% CI 2 to 3; low‐certainty evidence). Risk of spontaneous laxations in the medium term was over tenfold greater with methylnaltrexone (RR 8.15, 95% CI 4.76 to 13.95, 2 trials, 305 participants, I² = 47%. NNTB 2, 95% CI 2 to 2; moderate‐certainty evidence). Low‐certainty evidence showed methylnaltrexone reduced the risk of opioid withdrawal symptoms, and did not increase risk of a serious AE (RR 0.59, 95% CI 0.38 to 0.93. I² = 0%; 2 trials, 364 participants). The risk of AEs was higher for methylnaltrexone (low‐certainty evidence). </p> <p><b>Lower‐dose subcutaneous methylnaltrexone versus higher dose</b> </p> <p>There was little to no difference in risk of spontaneous laxations in the medium‐term (1 mg versus 5 mg or greater: RR 2.91, 95% CI 0.82 to 10.39; 1 trial, 26 participants very low‐certainty evidence), or in patient assessment of improvement in bowel status (RR 0.98, 95% CI 0.71 to 1.35, 1 trial, 102 participants; low‐certainty evidence). Medium‐term assessment of spontaneous laxations and serious AEs not reported. There was little to no difference in symptoms of opioid withdrawal (MD ‐0.25, 95% CI ‐0.84 to 0.34, 1 trial, 102 participants) or occurrence of AEs (low‐certainty evidence). </p> </section> <section id="CD006332-sec-0007"> <h3 class="title" id="CD006332-sec-0007">Authors' conclusions</h3> <p>This update's findings for naldemedine and naloxone with oxycodone have been strengthened with two new trials, but conclusions have not changed. Moderate‐certainty evidence for oral naldemedine on risk of spontaneous laxations and non‐serious AEs suggests in people with cancer that naldemedine may improve bowel function over two weeks and increase the risk of AEs. There was low‐certainty evidence on serious AEs. Moderate‐certainty evidence for methylnaltrexone on spontaneous laxations over two weeks suggests subcutaneous methylnaltrexone may improve bowel function in people receiving palliative care, but certainty of evidence for AEs was low. More trials are needed, more evaluation of AEs, outcomes patients rate as important, and in children. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006332-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006332-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006332-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006332-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006332-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006332-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006332-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006332-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006332-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006332-abs-0002" lang="en"> <h3>Mu‐opioid antagonists for bowel dysfunction due to opioids in people with cancer and people receiving palliative care </h3> <p><b>Background</b> </p> <p>Opioids (morphine‐like drugs) are used to treat severe pain, but they may cause bowel dysfunction including constipation, incomplete evacuation of the bowels, bloating, and increased reflux (flowing back) of stomach contents into the oesophagus (food pipe). This is because receptors for opioids are found in the gut. Opioid‐induced bowel dysfunction may be so severe that people choose to limit pain relief to improve bowel function. Opioid‐induced bowel dysfunction is common in people with cancer and those receiving palliative care (when a cure is no longer possible). Laxatives are often the first‐choice treatment for opioid‐induced bowel dysfunction. They may not always work. Mu‐opioid antagonists are specific medicines for opioid‐induced bowel dysfunction that have been developed to help reduce the effect of opioids (in the gut. A possible side effect of this treatment however, is reduced pain relief. </p> <p><b>Trial characteristics</b> </p> <p>The aim of this updated review was to determine what we know about the effectiveness and safety of mu‐opioid antagonists (MOABs) for the management of opioid‐induced bowel dysfunction in people with cancer or receiving palliative care. We only included randomised controlled trials as they provide the most reliable evidence. Randomised controlled trials are a type of study where people are randomly assorted into groups to test interventions, treatments, or drugs. It means that an individual has the same chance of having each intervention, treatment or drug. </p> <p>We found trials that evaluated the mu‐opioid antagonists naldemedine, methylnaltrexone, and naloxone. The trial comparison groups could be a placebo (a substance with no known active effect), usual care, the mu‐opioid antagonist at different dose, or in combination with other drugs or another treatment such as a different mu‐opioid antagonist. </p> <p><b>Key results</b> </p> <p>Our search to 20th December 2021 found 10 trials involving 1343 adults. The mu‐opioid antagonists evaluated in people with cancer were oral naldemedine and naloxone taken in combination with an opioid treatment (for pain). The other mu‐opioid antaGonist evaluated in the trials was methylnaltrexone. It was given by injection and evaluated in palliative care where most participants had advanced cancer. </p> <p>Naldemedine or methylnaltrexone were compared with placebo. Naloxone was compared with a placebo or opioid treatment only. </p> <p>The overall confidence as in certainty we have in the evidence is very low to moderate (very uncertain to somewhat certain). There were problems with the design of studies, including under‐reporting of trial methods. </p> <p><i>Bowel movements</i> </p> <p>Within two weeks of treatment of naldemedine or methylnaltrexone bowel movement probably increases (moderate/somewhat certain evidence); trials did not measure the effects of naloxone within two weeks. There was low (uncertain evidence) confidence that patients found naloxone taken with an opioid treatment and methylnaltrexone improved their symptoms of constipation. Trials of naldemedine did not measure patients assessment of improvement in symptoms of constipation. </p> <p><i>Pain relief</i> </p> <p>There was low confidence in the evidence that there was no impact from naloxone in combination with an opioid or from methylnaltrexone on the treatment relief from pain. There was low (uncertain) confidence in the evidence naldemedine did not change treatment relief from pain. </p> <p><i>Risk of serious side effects (e.g. hospitalisation, life‐threatening, or fatal) and other side effects</i> </p> <p>There was low (uncertain) confidence that naldemedine or methylnaltrexone did not cause an increase in the risk of serious side effects. There was low confidence in the evidence that naloxone in combination with an opioid did not increase the risk of serious side effects (adverse reaction). </p> <p>Naldemedine probably did not increase the risk of other non‐serious side effects (moderate certainty/somewhat certain evidence). There was low confidence in the evidence that naloxone taken with opioid treatment did not cause an increase in the risk of a side effect. For methylnaltrexone there was low confidence in the evidence that it did not increase the risk of a side effect.  </p> <p><b>Conclusion</b> </p> <p>There was moderate‐certainty evidence that naldemedine taken orally improved bowel function within two weeks in adults with cancer and opioid‐induced bowel dysfunction but increased the risk of side effects, and that methylnaltrexone taken as an injection improved bowel function over two weeks in people receiving palliative care. The results of this review need to be interpreted with caution as they were not obtained from evidence that was of high‐certainty. Outcome evaluations were limited, in particular not all TRIALS measured patient assessment of improvement in bowel movements. There were no studies in children. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006332-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006332-sec-0132"></div> <h3 class="title" id="CD006332-sec-0133">Implications for practice</h3> <section id="CD006332-sec-0133"> <section id="CD006332-sec-0134"> <h5 class="title">For people with cancer and people receiving palliative care with opioid‐induced bowel dysfunction </h5> <p>In people with cancer who have opioid‐induced bowel dysfunction (OIBD), despite laxative use, we found moderate certainty in the evidence that the mu‐opioid antagonist (MOA), naldemedine, taken orally may improve bowel function within two weeks of the start of administration. We found very low certainty in the evidence whether naldemedine has little to no increase in risk of increasing symptoms of opioid withdrawal. We found low‐certainty evidence that naldemedine has little to no increase in chances of a serious adverse event. We found moderate‐certainty evidence that naldemedine increases the chances of experiencing a non‐serious adverse event. The most common non‐serious adverse event is diarrhoea. Patient assessment of improvement in bowel status was not reported. </p> <p>Trials on the effect of naloxone alone or in combination with oxycodone in treating OIBD in people with cancer did not measure bowel function within two weeks of the start of administration. For naloxone in combination with oxycodone we found low‐certainty evidence that it has no impact on symptoms of opioid withdrawal and adverse events, and very low‐certainty evidence that it has no effect on risk of serious adverse events (SAEs). </p> <p>We found moderate‐certainty evidence in palliative care that when conventional laxatives have failed that the MOA, methylnaltrexone, administered subcutaneously, can be successful within two weeks in improving bowel function. We found low‐certainty evidence that methylnaltrexone improves peoples assessment of their bowel status, improves within 24 hours bowel function, and that it has little to no effect on symptoms of opioid withdrawal. There is low‐certainty evidence that it does not increase the chances of SAEs and that it has little to no effect on adverse events. </p> <p>We found no studies on children, and no head‐to‐head trials of MOAs (two MOAs compared with each other). </p> </section> <section id="CD006332-sec-0135"> <h5 class="title">For clinicians</h5> <p>In this update, our overall conclusions have not changed. For people with cancer, there is moderate‐certainty evidence that oral naldemedine may be effective within two weeks of administration in inducing laxation where conventional laxatives have failed. Patient assessment of change in bowel status was not reported in the included trials. There is low‐certainty evidence that naldemedine has little to no impact on symptoms of opioid withdrawal. There were in one of the two trials that assessed naldemedine five serious adverse events in participants in the naldemedine arm, and no serious adverse events in participants taking placebo. It is not clear if any of the events were related to naldemedine. We judged this as low‐certainty evidence on whether this drug increases the risk of serious adverse events. There was low‐certainty evidence that naldemedine did increases the chances of experiencing another (non‐serious) adverse event; commonly this was diarrhoea. </p> <p>In palliative care where conventional laxatives have failed, there is low‐certainty evidence that methylnaltrexone is effective in the short term (within 24 hours). Over two weeks, there is moderate‐certainty evidence that methylnaltrexone is effective in inducing laxation for a proportion of people in palliative care with OIBD There is low‐certainty evidence that methylnaltrexone improves peoples assessment of their bowel status. There is low‐certainty evidence that methylnaltrexone has little to no impact on symptoms of opioid withdrawal. Methylnaltrexone may be associated with an increase in certain adverse events, such as abdominal pain and flatulence but this evidence is of low certainty. There is low‐certainty evidence to suggest that this medication has little to no increase in the risk of serious adverse events. </p> <p>Trials on naloxone alone or in combination with oxycodone in treating OIBD in people with cancer did not measure laxation response within two weeks of drug administration. For naloxone in combination with oxycodone there is low‐certainty evidence to support the suggestion that it has little to no impact on analgesia or in the risk of adverse events. There is very low‐certainty evidence that naloxone in combination with oxycodone has little to no impact on the risk of SAEs. </p> <p>These treatments were tested in studies that excluded patients in situations that may affect efficacy by compounding constipation such as any disease processes suggestive of abnormalities of the gastrointestinal tract, and chemotherapy. All these treatments are unlikely to be effective in all people and not all outcomes have been fully evaluated, for example, treatment satisfaction and preference. We found no studies on children. There have been no head‐to‐head trials, so it is difficult to compare their impact on OIBD. </p> </section> <section id="CD006332-sec-0136"> <h5 class="title">For policy makers</h5> <p>In adults in palliative care, when conventional laxatives have failed, subcutaneous methylnaltrexone at two weeks, and in people with cancer oral naldemedine at two weeks may be successful in improving bowel function. In adults with cancer and those receiving palliative care, laxatives are first‐line drug therapy. When conventional laxatives have failed, subcutaneous methylnaltrexone is a second‐line therapy if an immediate response is required. Oral naldemedine is a second‐line therapy if an immediate laxation is not essential. </p> </section> <section id="CD006332-sec-0137"> <h5 class="title">For funders of the intervention</h5> <p>There is sufficient evidence in palliative care for adults that when conventional laxatives have failed subcutaneous methylnaltrexone may improve bowel function within two weeks and low‐certainty evidence it may improve function within 24 hours. There is sufficient evidence that in adults with cancer oral naldemedine may improve bowel function within two weeks of start of administration. Evidence on naldemedine impact on bowel function is not reported. We would encourage funders to consider, when conventional laxatives have failed, subcutaneous methylnaltrexone as a second‐line therapy if an immediate response is required. Oral naldemedine is a second‐line therapy if an immediate laxation is not essential. </p> </section> </section> <h3 class="title" id="CD006332-sec-0138">Implications for research</h3> <section id="CD006332-sec-0138"> <p>We found four trials that were ongoing, and six awaiting further detail on whether they fulfilled our eligibility criteria. This includes evaluation of naloxegol. Therefore, some of the suggestions listed in this section may need to be modified once the results of these trials are published. Two ongoing trials, which were excluded based on our current inclusion criteria of treatment for people with OIBD, are evaluating whether naldemedine alone or as an adjunct may prevent OIBD starting (<a href="./references#CD006332-bbs2-0012" title="Hamano Jun. A Multicenter, double-blind, randomized, placebo-controlled trial of the preventive effect of naldemedine on opioid-induced constipation. rctportal.niph.go.jp2021. ">jRCTs031200397</a>; <a href="./references#CD006332-bbs2-0016" title="OzakiA , KessokuT , IwakiM , KobayashiT , YoshiharaT , KatoT , et al. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. Trials2020;21(1):453. ">Ozaki 2020</a>). This suggests any future update of this review may want to also consider use of MOAs as a preventative treatment in these patient groups. </p> <section id="CD006332-sec-0139"> <h5 class="title">General</h5> <p>Rigorous randomised controlled trials (RCTs) measuring standardised and clinically‐ and participant‐relevant outcomes are needed to establish the effectiveness and safety of MOAs. Head‐to‐head comparisons should be considered. Trials should be reported according to the CONSORT statement and its extensions such as for cross‐over trials (<a href="./references#CD006332-bbs2-0069" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine2010;152:1-7.">Schulz 2010</a>). </p> </section> <section id="CD006332-sec-0140"> <h5 class="title">Design</h5> <p>Attrition rates in the included trials and the relatively small numbers of eligible participants in any one palliative care treatment unit suggest that trials should involve participants recruited from multiple centres. </p> </section> <section id="CD006332-sec-0141"> <h5 class="title">Measurement (endpoints)</h5> <p>There is a need to include multiple measures in addition to laxation response, these include analgesia effect, pain intensity, tolerability, quality of life, participant preference, and costs. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006332-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006332-sec-0008"></div> <div class="table" id="CD006332-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Naldemedine compared to placebo for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Naldemedine compared to placebo for opioid‐induced bowel dysfunction for people with cancer </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction </p> <p><b>Settings:</b> not stated </p> <p><b>Intervention:</b> naldemedine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Naldemedine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the short term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the medium term</b><sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>718 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.00</b> (1.59 to 2.52) <b>NNTB</b> 3 (3 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change in bowel status at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms of opioid withdrawal</b><sup>e</sup><b>in the</b> </p> <p><b>medium term</b><sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in opioid withdrawal was 0.0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in opioid withdrawal was 0.1 <b>lower</b> 0.1 mg; 0.3 <b>higher</b> 0.2 mg, 0.2 <b>higher</b> 0.4 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naldemedine 0.1 mg: <b>MD ‐0.10</b> (‐0.56 to 0.36); naldemedine  0.2 mg: <b>MD 0.30</b> (‐0.21 to 0.81); naldemedine  0.4 mg: <b>MD 0.20</b> (‐0.36 to 0.76)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 in comparison with naldemedine 0.1 mg and 0.4 mg, 114 in comparison with 0.2mg (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.34</b> (0.85 to 13.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>613 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> (1.19 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>RR:</b> risk ratio; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Defined in both trials as having 3 or more laxations (not induced by rescue medication) a week/who had an increase of one of more laxations (not induced by rescue medication) a week from baseline </p> <p><sup>b</sup> Within first 24 hours </p> <p><sup>c</sup> Over two weeks </p> <p><sup>d</sup> Downgraded by one level for serious study limitations because of high risk of attrition bias in one study </p> <p>e Measured by the Clinical Opioid Withdrawal Scale. Lower scores indicate symptoms of lower severity. Score of 5‐12 mild, 13‐24 moderate, 25‐36 moderately severe, more than 36 severe withdrawal. Maximum score 48.<br/><sup>f</sup> Downgraded by two levels for very serious study limitations because all of the data were derived from only one study with a high risk of attrition bias </p> <p><sup>g</sup> Downgraded by one level for serious imprecision as data were derived from fewer than 400 participants </p> <p><sup>h</sup> Serious non‐fatal events were reported, definition of what fits this criteria was not provided </p> <p><sup>i</sup> Downgraded by one level for serious imprecision due to wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006332-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Low dose naldemedine compared to higher doses for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Low dose naldemedine compared to higher‐dose for opioid‐induced bowel dysfunction for people with cancer </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction </p> <p><b>Setting:</b> not stated </p> <p><b>Intervention:</b> Naldemedine 0.1 mg daily </p> <p><b>Comparison:</b> Naldemedine 0.4 mg daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher dose</b> </p> <p><b>0.4 mg daily</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower dose</b> </p> <p><b>0.1 mg daily</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the short term</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the medium term<sup>b,c</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>821 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> (0.53 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change bowel status at end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms of opioid withdrawal</b><sup>f</sup><b>in the medium term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> <p>Mean change in opioid withdrawal</p> <p>0.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean change in opioid withdrawal <b>‐0.3 lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD </b> </p> <p><b>‐0.30</b> [‐0.85, 0.25] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0.2 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.25</b> (0.03, 2.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d.e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>786 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>660 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b> (0.67,1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; ; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Within first 24 hours following intervention and comparison treatment </p> <p><sup>b</sup> Defined in study as having 3 or more laxations (not induced by rescue medication) a week/who had an increase of one of more laxations (not induced by reduce medication) a week from baseline </p> <p><sup>c</sup> Measured over two weeks<br/><sup>d</sup> Downgraded by one level for serious study limitations due to unclear risk of bias (reporting bias) </p> <p><sup>e</sup> Downgraded by one level for serious imprecision (fewer than 400 participants for continuous data or fewer than 300 events for dichotomous data). </p> <p><sup>f</sup>Measured by the Clinical Opioid Withdrawal Scale. Lower scores indicate symptoms of lower severity. Score of 5‐12 mild, 13‐24 moderate, 25‐36 moderately severe, more than 36 severe withdrawal. Maximum score 48. </p> <p><sup>g</sup> Serious non‐fatal events were analysed, no further definition by study authors </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006332-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Naloxone compared with placebo for opioid‐induced bowel dysfunction in people with cancer and receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Naloxone compared with placebo for people with cancer and receiving palliative care with opioid‐induced bowel dysfunction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer and receiving palliative care with opioid‐induced bowel dysfunction </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> naloxone </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Naloxone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the short term</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the medium term<sup>b</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change in bowel status at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms of opioid withdrawal in the medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full data not provided </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Within first 24 hours </p> <p><sup>b</sup> Between 1 and 14 days </p> <p><sup>c </sup>Downgraded by one level for serious study limitations: unclear risk of bias (reporting bias)  </p> <p><sup>d </sup> Downgraded by two levels for very serious imprecision as sparse data (17 participants) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006332-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Naloxone + oxycodone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Naloxone + oxycodone prolonged release tablets compared with oxycodone prolonged‐released tablets for people with cancer and opioid‐induced bowel dysfunction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> naloxone + oxycodone prolonged‐release tablets (OXN PR) </p> <p><b>Comparison:</b> oxycodone prolonged‐released tablets (OXY PR) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oxycodone (OXY PR)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oxycodone + naloxone (OXN PR)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the short term</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>—</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the medium term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: Patient assessment of change in bowel status</b><sup>c</sup><b>at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>data not provided</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>data not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study 1: Mean change ‐ 11.14 (‐19.03, ‐3.24)</p> <p>Study 2: Little to no change p value = 0.264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Full data not provided in either study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms of opioid withdrawal</b><sup>f</sup><b>in the medium term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 7.27</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 0.63 <b>lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐0.63</b> (‐2.44, 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> (0.44 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d,e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>584 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01 </b>(0.87 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; ; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Within first 24 hours </p> <p><sup>b</sup> Between 1 and 14 days </p> <p><sup>c</sup> Measured in one study using 3‐item Bowel Function Index, where lower scores indicate better bowel function, and scores above 28.8 indicate constipation. Scores range from 0 to 100. In the other study change in bowel habits was measured using a 3‐point Likert Scale (worsened, no change, improved) </p> <p><sup>d</sup> Downgraded by one level because of serious study limitations (unclear risk of reporting bias)<br/><sup>e</sup> Downgraded by one level because of serious imprecision (data from fewer than 400 participants) </p> <p><sup>f</sup> Measured using the 16‐item Modified Subjective Opiate Withdrawal Scale. Lower scores indicate symptoms of lower severity. Range 0 to 64. Further scoring details not reported </p> <p><sup>g</sup> Not defined by trial authors </p> <p><sup>h </sup>Downgraded by one level because of serious unexplained inconsistency (substantial heterogeneity I<sup>2</sup> = 55%) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006332-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction </p> <p><b>Setting:</b> hospital and community </p> <p><b>Intervention:</b> methylnaltrexone </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with</b> </p> <p><b>methylnaltrexone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the short term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>701 per 1000 (625 to 770)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.97</b> (2.13 to 4.13) <b>NNTB 3</b> (2 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the medium term</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>671 per 1000<br/>(590 to 745) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.15</b> (4.76 to 13.95) <b>NNTB 2</b> (2 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change in bowel status</b><sup>g</sup><b>at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>252 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>567 per 1000</p> <p>(488 to 644)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.32</b> (1.64 to 3.27)* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion reporting improvement</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms of opioid withdrawal</b><sup>h</sup><b>in the medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean 8.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean 0.2<b>lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐0.20</b> (‐0.80 to 0.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000<br/>(88 to 219) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> (0.38 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>797 per 1000<br/>(745 to 869) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b> </p> <p>(CI 1.05 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity was substantial (74%). We did not undertake a sensitivity analyses as none of our predefined criteria for undertaking one were matched. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>NNTB:</b> number needed to treat for an additional beneficial outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Measured by self‐report or clinician report </p> <p><sup>b</sup> Within first 24 hours following intervention and comparison treatment </p> <p><sup>c</sup>Downgraded once for serious study limitations because of unclear risk of reporting bias </p> <p><sup>d</sup>Downgraded once for serious imprecision (data fewer than 400 participants) </p> <p><sup>e</sup>Between 1 and 14 days </p> <p><sup>f</sup>As the effect size was large we did not downgrade for imprecision </p> <p><sup>g</sup>Measured in both studies using the Global Clinical Impression of Change, a scale ranging from 1 to 7, with higher scores indicating better bowel function </p> <p><sup>h</sup>Measured using the modified Himmelsbach Opioid Withdrawal Scale. Lower scores indicate symptoms of lower severity. Total scores range from 7 to 28.<br/><sup>i </sup>Not defined by trial authors </p> <p><sup>j</sup>Downgraded once for serious inconsistency because of substantial heterogeneity across trials </p> <p>*In one trial with 2 comparisons with the same control arm, we combined the intervention groups to form a single pairwise comparison </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006332-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Methylnaltrexone lower dose compared to higher dose for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methylnaltrexone 1 mg compared to methylnaltrexone 5 mg or greater for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction </p> <p><b>Setting:</b> hospital and community </p> <p><b>Intervention 1:</b> lower‐dose methylnaltrexone (study 1: 3 doses, 1 week, 1 mg; study 2: 1 dose, 0.15 mg/kg) </p> <p><b>Intervention 2:</b> higher‐dose methylnaltrexone (study 1: 3 doses, 1 week, 5‐20 mg; study 2: 1 dose, 0.30 mg/kg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher dose (5 mg)?</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower dose (1 mg)?</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the short term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: 609 per 1000</p> <p>Study 2: 639 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>499 per 1000</b> (250 to 100) </p> <p>Study 2: <b>681 per 1000</b> (515 to 904) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>RR 0.21</b> (0.03 to 1.41) </p> <p>Study 2: </p> <p><b>RR 1.06</b> (0.77 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 (2 studies) Study 1: n = 33</p> <p>Study 2: n = 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study data not combined as methylnaltrexone dosing differed substantially per study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a,</sup><b>in the medium term</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>647 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222<b>per 1000</b>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <b>RR 2.91</b> (0.82 to 10.39) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: patient assessment of change in bowel status</b><sup>g</sup><b>at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> (0.71 to 1.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms of opioid withdrawal in the medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>mean 0.25 <b>lower </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.25 (‐0.84 to 0.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not combined as methylnaltrexone dosing differed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In one trial, 15 serious adverse events occurred during the randomised trial phase but it does not report what arm the events occurred in.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: 1000 per 1000</p> <p>Study 2: 800 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>1000 per 1000</b> (1000 to 1000) </p> <p>Study 2: <b>723 per 1000</b> </p> <p>(580 to 902)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>RR 1.00</b> (1.00 to 1.00) </p> <p>Study 2: <b>RR 0.90</b> (0.73 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 (2 studies)</p> <p>Study 1: n = 33</p> <p>Study 2: n = 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study data not combined as methylnaltrexone dosing differed substantially per study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Measured by clinician or self‐report </p> <p><sup>b</sup> Within first 24 hours following intervention and comparison treatment </p> <p><sup>c</sup> Downgraded by one level for serious study limitations: unclear risk of bias (reporting bias) </p> <p><sup>d</sup> Downgraded by one level for serious imprecision as fewer than 400 participants. </p> <p><sup>e</sup>Between 1 and 14 days </p> <p><sup>f</sup> Downgraded by two levels for very serious imprecision as sparse data 26 participants and wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006332-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006332-sec-0009"></div> <p>This is an update of the review first published in 2008 (<a href="./references#CD006332-bbs2-0079" title="McNicolED , BoyceD , SchumannR , CarrDB . Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD006332. [DOI: 10.1002/14651858.CD006332.pub2]">McNicol 2008</a>), and last updated in 2018 (<a href="./references#CD006332-bbs2-0077" title="CandyB , JonesL , VickerstaffV , LarkinPJ , StonesP . Mu-opioid antagonists for opioid induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD006332. [DOI: 10.1002/14651858.CD006332.pub3]">Candy 2018</a>). It is a partial update of the review published in 2008 entitled Mu‐opioid antagonists for opioid‐induced bowl dysfunction (<a href="./references#CD006332-bbs2-0079" title="McNicolED , BoyceD , SchumannR , CarrDB . Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD006332. [DOI: 10.1002/14651858.CD006332.pub2]">McNicol 2008</a>). Since publication in 2008, there has been an increase in the number of trials on mu‐opioid antagonists (a drug designed to neutralise the effect of opioids on bowel function), and this current review and its last update critiques evidence only for people with cancer and people receiving palliative care. </p> <section id="CD006332-sec-0010"> <h3 class="title" id="CD006332-sec-0010">Description of the condition</h3> <p>Opioids, such as morphine sulphate, oxycodone, and fentanyl, are potent analgesics (medicines to relieve pain). They are recommended in clinical guidelines by the World Health Organization (WHO) including for the management of moderate‐to‐severe pain from cancer and other populations such as people needing palliative care (<a href="./references#CD006332-bbs2-0075" title="World Health Organization. WHO's cancer pain ladder for adults, 2016. who.int/cancer/palliative/painladder/en/ (accessed 17 November 2016).">WHO 2016</a>). They are widely used, although globally there is wide variation suggesting an under‐utilisation of opioids for pain management in some locations (<a href="./references#CD006332-bbs2-0056" title="ManjianiD , PaulDB , KunnumpurathS , KayeAD , VadiveluN . Availability and utilization of opioids for pain management: global issues. Ochsner Journal2014;14:208-15.">Manjiani 2014</a>). </p> <p>However, opioids are associated with adverse events. The most common and disabling of these is bowel dysfunction, which can be severe enough for a person to limit their opioid use (<a href="./references#CD006332-bbs2-0037" title="CookSF , LanzaL , ZhouX , SweeneyCT , GossD , HollisK , et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Alimentary Pharmacology and Therapeutics2008;27:1224-32.">Cook 2008</a>). Opioids, regardless of the method of administration (oral, parenteral, transdermal), interfere with gastrointestinal propulsive motility (<a href="./references#CD006332-bbs2-0053" title="LeppertW . The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Advances in Therapy2010;27:714-30.">Leppert 2010</a>). Opioids increase absorption of fluids from the intestine and decrease epithelial secretion. They delay gastric emptying and decrease peristalsis in the gut. </p> <p>Opioid‐induced bowel dysfunction (OIBD) has been described as quote: "A change when initiating opioid therapy from baseline bowel habits that is characterised by any of the following: reduced bowel movement frequency (conventionally less than 3 per week), development or worsening of straining to pass bowel movements, a sense of incomplete rectal evacuation, or harder stool consistency" (<a href="./references#CD006332-bbs2-0051" title="KumarNB . Dysfunction of the bowel/constipation. In: Nutritional Management of Cancer Treatment Effects. Berlin/Heidelberg: Springer-Verlag, 2012.">Kumar 2012</a>). It may even lead to stool impaction (<a href="./references#CD006332-bbs2-0033" title="CamilleriM , DrossmanDA , BeckerG , WebsterLR , DaviesAN , MaweGM . Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterology and Motility2014;26:1386-95.">Camilleri 2014</a>). In addition to constipation, OIBD describes a constellation of symptoms including bloating, abdominal distention, gastric reflux, abdominal cramping, dry mouth, epigastric fullness, nausea, and vomiting (<a href="./references#CD006332-bbs2-0054" title="LeppertW . Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Design, Development and Therapy2015;9:2215-31.">Leppert 2015</a>; <a href="./references#CD006332-bbs2-0065" title="PappagalloM . Incidence, prevalence, and management of opioid bowel dysfunction. American Journal of Surgery2001;182:11S-18S.">Pappagallo 2001</a>). It can cause psychological distress and agitation in terminally ill people. OIBD increases health service use, sometimes necessitates hospitalisation, and it can dramatically reduce an already compromised quality of life. It may lead to people under‐treating their pain (<a href="./references#CD006332-bbs2-0066" title="PizziLT , TonerR , FoleyK , ThomsonE , ChowW , KimM , et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy2012;32:502-14.">Pizzi 2012</a>); however, since the dose that produces constipation may only be 25% of that required for adequate analgesia, dose reduction is not an appropriate option for management of OIBD (<a href="./references#CD006332-bbs2-0050" title="KetwarroGA , ChengV , LemboA . Opioid-induced bowel dysfunction. Current Gastroenterology Reports2013;15:344.">Ketwaroo 2013</a>). </p> <p>In people with cancer, hospice populations and people with advanced disease, the estimated incidence of OIBD is high, from 60% to 90% (<a href="./references#CD006332-bbs2-0042" title="GlareP , WalshD , SheehanD . The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. American Journal of Hospice Palliative Care2006;23:229-35.">Glare 2006</a>; <a href="./references#CD006332-bbs2-0064" title="PanchalSJ , Muller-SchwefeP , WurzelmannJI . Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. International Journal of Clinical Practice2007;61:1181-7.">Panchal 2007</a>; <a href="./references#CD006332-bbs2-0073" title="SykesNP . The relationship between opioid use and laxative use in terminally ill cancer patients. Palliative Medicine1998;12:375-82.">Sykes 1998</a>). Although these estimates are relatively old, there is no evidence to suggest that this is no longer the case. Moreover, surveys have found that large proportion of people skip, decrease or discontinue opioid use because of bowel dysfunction, thereby preferring pain in preference to constipation (<a href="./references#CD006332-bbs2-0043" title="GuptaS , PatelH , ScopelJ , ModyRR . Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey. Journal of Opioid Management2015;11:325-38.">Gupta 2015</a>; <a href="./references#CD006332-bbs2-0037" title="CookSF , LanzaL , ZhouX , SweeneyCT , GossD , HollisK , et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Alimentary Pharmacology and Therapeutics2008;27:1224-32.">Cook 2008</a>; <a href="./references#CD006332-bbs2-0055" title="LoCasaleRJ , DattoC , WilsonH , YeomansK , CoyneKS . The burden of opioid-induced constipation: discordance between patient and health provider reports. Journal of Management Care and Speciality Pharmacy2016;22:236045.">LoCasale 2016</a>). </p> </section> <section id="CD006332-sec-0011"> <h3 class="title" id="CD006332-sec-0011">Description of the intervention</h3> <p>The recommended and commonly prescribed preventive and management treatment of OIBD in palliative care and advanced disease is the use of a laxative stimulant and a stool softener, in addition to general measures such as increased food, fibre‐rich diet, fluid intake, physical activity, and privacy during defecation (<a href="./references#CD006332-bbs2-0061" title="National Institute for Health and Care Excellence. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults, 2012. www.nice.org.uk/guidance/cg140/resources (date accessed 17 November 2016).">NICE 2016</a>; <a href="./references#CD006332-bbs2-0052" title="LarkinPJ , ChernyNI , La CarpiaD , GuglielmoM , OstgatheC , ScotteF , et al on behalf of the ESMO Guidelines Committee. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology2018;29:iv111-25.">Larkin 2018</a>; <a href="./references#CD006332-bbs2-0072" title="SeraL , McPhersonML . Management of opioid-induced constipation in hospice patients. American Journal of Hospice and Palliative Medicine2018;35:330-5.">Sera 2018</a>). These measures are not always effective; in people taking opioids, it is estimated that over 80% of people remain constipated despite regular use of laxatives (<a href="./references#CD006332-bbs2-0038" title="CoyneKS , LoCasaleRJ , DattoCJ . Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoeconomic Outcomes Research2014;6:269-81.">Coyne 2014</a>; <a href="./references#CD006332-bbs2-0039" title="DiegoL , AtayeeR , HelmonsP , HsiaoG , vonGuntenCF . Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opinion on Investigational Drugs2011;20:1047-56.">Diego 2011</a>). This inadequate response can be defined as having at least one opioid‐induced constipation symptom (incomplete bowel movement, hard stools, straining or false alarms) of moderate severity, while taking at least one type of laxative over four days within the past two weeks. </p> <p>Mu‐opioid antagonists (MOAs), such as methylnaltrexone, naloxone, and naloxegol, are designed specifically to target the pathophysiology of OIBD by 'neutralising' the constipating effect of the opioid. Methylnaltrexone is licensed for the treatment of opioid‐induced constipation in palliative care in more than 50 countries (<a href="./references#CD006332-bbs2-0030" title="BaderS , DurkT , BeckerG . Methylnaltrexone for the treatment of opioid-induced constipation. Expert Review of Gastroenterology and Hepatology2013;7:13-26.">Bader 2013</a>). In clinical guidelines, where methylnaltrexone or other MOAs are considered, it is described to act as an augmentation to laxatives or as an alternative when laxatives fail (European Association of Palliative Care, <a href="./references#CD006332-bbs2-0035" title="CaraceniA , HanksG , KaasaS , BennettMI , BrunelliC , ChernyN , et al, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology2012;13:e58-68.">Caraceni 2012</a>; European Society of Medical Oncology (ESMO), <a href="./references#CD006332-bbs2-0052" title="LarkinPJ , ChernyNI , La CarpiaD , GuglielmoM , OstgatheC , ScotteF , et al on behalf of the ESMO Guidelines Committee. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology2018;29:iv111-25.">Larkin 2018</a>), and should be used only under advice from a specialist palliative care clinician (<a href="./references#CD006332-bbs2-0071" title="NHS Scotland. Scottish Palliative Care Guidelines: about the guidelines, 2014. www.palliativecareguidelines.scot.nhs.uk/guidelines (accessed 17 November 2016).">Scottish Palliative Care Guidelines 2014</a>). The National Institute for Health and Care Excellence (NICE) recommends naldemedine (<a href="./references#CD006332-bbs2-0063" title="National Institute for Clinical Excellence. Naldemedine for treating opioid-induced constipation (TA651) [2020]. nice.org.uk (date accessed 29 June 2022).">NICE 2020</a>) and naloxegol (<a href="./references#CD006332-bbs2-0060" title="National Institute for Clinical Execellence. Naloxegol for treating opioid-induced constipation, 2015. nice.org.uk (date accessed 17 November 2016).">NICE 2015</a>) for treating OIBD in adults who have had laxative treatment. This is based on both evidence on effect and cost. NICE does not recommend methylnaltrexone because no evidence submission was received from the manufacturer of the technology (<a href="./references#CD006332-bbs2-0062" title="National Institute for Clinical Excellence. Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal), 2017. nice.org.uk (date accessed 19 April 2017).">NICE 2017</a>). </p> </section> <section id="CD006332-sec-0012"> <h3 class="title" id="CD006332-sec-0012">How the intervention might work</h3> <p>Opioids mediate their gastrointestinal and analgesic effects through the same subclasses of opioid receptors in the human body: mu, kappa, and delta. How each receptor type is involved in OIBD is not fully understood (<a href="./references#CD006332-bbs2-0026" title="NeefjesEC , van derVorstMJ , BoddaertMS , ZuurmondWW , van derVlietHJ , BeekerA , et al. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care2014;13:42. ">Neefjes 2014</a>). The peripheral opioid effect on mu‐opioid receptors in the gut wall may play a main role in OIBD (<a href="./references#CD006332-bbs2-0053" title="LeppertW . The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Advances in Therapy2010;27:714-30.">Leppert 2010</a>). Co‐ordination of motility is disrupted by activation of the mu‐opioid receptors that inhibit excitatory and inhibitory neural pathways within the enteric nervous system. </p> <p>One approach for dissociation of the analgesic effect of opioids is to separate the opioid's central activity from its peripheral activity (<a href="./references#CD006332-bbs2-0074" title="Wang C-Z, YuanCS . Pharmacologic treatment of opioid-induced constipation. Drugs2013;22(10):1225-7.">Wang 2013</a>). This may be achieved with a peripherally acting opioid receptor antagonist with limited ability to cross the blood‐brain barrier and which therefore does not interfere with analgesia (<a href="./references#CD006332-bbs2-0031" title="BrownDR , GoldbergLI . The use of quaternary narcotic antagonists in opiate research. Neuropharmacology1985;24:181-91.">Brown 1985</a>). Alternatively, this can be achieved by use of a preparation that undergoes extensive 'first‐pass' metabolism by the liver and so does not enter the systemic circulation. </p> <p>There are several MOAs in use. Naloxone is commercially available; it is centrally acting but has a narrow therapeutic effect with certain doses reversing desirable analgesia (<a href="./references#CD006332-bbs2-0032" title="Camilleri 2011. Opioid-induced constipation: challenges and therapeutic opportunities. American Journal of Gastroenterology2011;106:835-42.">Camilleri 2011</a>). It undergoes extensive first‐pass metabolism and in the correct dosage it does not reverse the analgesic effect of opioids. It is administered orally. The development of a prolonged‐release preparation of naloxone to allow as much cover of the small and large intestine as possible when used with oxycodone has led to further studies of the compound (<a href="./references#CD006332-bbs2-0032" title="Camilleri 2011. Opioid-induced constipation: challenges and therapeutic opportunities. American Journal of Gastroenterology2011;106:835-42.">Camilleri 2011</a>). There are several other preparations that do not cross the blood‐brain barrier and these include alvimopan, methylnaltrexone, naloxegol, and naldemedine. Alvimopan has a high affinity for peripheral opioid receptors. It is only recommended for short‐term use, such as post‐surgery, because of the possibility of myocardial events (<a href="./references#CD006332-bbs2-0058" title="Pharmaceutical Manufacturing Research Services. Highlights of prescribing information, 2015. www.merck.com/product/usa/pi_circulars/e/entereg/entereg_pi.pdf (date accessed 28 March 2017).">Merck 2015</a>). It is contraindicated in people with advanced disease (<a href="./references#CD006332-bbs2-0054" title="LeppertW . Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Design, Development and Therapy2015;9:2215-31.">Leppert 2015</a>). Methylnaltrexone is less lipid soluble than naloxone and, therefore, less likely to cross the blood‐brain barrier. It is only currently available in subcutaneous formulation. Naloxegol, which is administered orally, has a polyethylene glycol moiety that limits its capacity to cross the blood‐brain barrier (<a href="./references#CD006332-bbs2-0067" title="PritchardD , BharuchaA . Management of opioid-induced constipation for people in palliative care. International Journal of Palliative Nursing2015;21:272-80.">Pritchard 2015</a>). Naldemedine is administered orally, and it is a derivative of naloxone, it has a large polar surface that reduces its ability to access the central nervous system (<a href="./references#CD006332-bbs2-0040" title="FDA. Clinical pharmacology and biophaceutics review: application number: 208854Orig1s000. accessdata.fda.gov2017.">FDA 2017</a>). </p> </section> <section id="CD006332-sec-0013"> <h3 class="title" id="CD006332-sec-0013">Why it is important to do this review</h3> <p>There are reviews of MOAs for OIBD across different populations (e.g. <a href="./references#CD006332-bbs2-0059" title="NeeJ , ZakariM , SugarmanMA , WhelanJ , HirschW , SultanS , et al. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clinical Gastroenterology Hepatology2018;16:1569-84.e2.">Nee 2018</a>; <a href="./references#CD006332-bbs2-0041" title="FordAC , BrennerDM , SchoenfeldPS . Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. American Journal of Gastroenterology2013;108:1566-74.">Ford 2013</a>). However, it is important to evaluate their effectiveness and safety specifically in cancer and in palliative care populations (<a href="./references#CD006332-bbs2-0029" title="BaderS , WeberM , BeckerG . Is the pharmacological treatment of constipation in palliative care evidence based? A systematic literature review. Der Schmerz.2012;26:568-86.">Bader 2012</a>; <a href="./references#CD006332-bbs2-0036" title="ClarkK , CurrowDC . Methylnaltrexone in palliative care: further research is needed. Journal of Pain and Symptom Management2014;47:e5-6.">Clark 2014</a>). This is because of the differences inherent in these groups that may impact, in a likely negative way, on the effect of MOAs. The impact may differ because of the multi‐factorial pathophysiology of constipation in people with cancer and advanced diseases (<a href="./references#CD006332-bbs2-0053" title="LeppertW . The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Advances in Therapy2010;27:714-30.">Leppert 2010</a>). This may include structural abnormalities such as bowel obstruction; pelvic tumours; radiation fibrosis; or metabolic disturbances such as dehydration, hypercalcaemia, and hypokalaemia. It may involve neurological disorders. There may also be general issues increasing the risk and complicating the management of OIBD such as advanced age, depression, drug sedation, chemotherapy, multiple therapies, and a lack of privacy provided as an inpatient for bowel evacuation. As the person's disease progresses, they may have increasing frailty, lower activity, reduced appetite, and eventually multiple organ failure, all of which may impact on bowel function (<a href="./references#CD006332-bbs2-0029" title="BaderS , WeberM , BeckerG . Is the pharmacological treatment of constipation in palliative care evidence based? A systematic literature review. Der Schmerz.2012;26:568-86.">Bader 2012</a>). Moreover, because of these factors, people with cancer and particularly people at a palliative care stage may have a higher risk than other, less ill populations of experiencing adverse events from MOAs. This review is an update and since its most recent publication we are aware of new trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006332-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006332-sec-0014"></div> <p>To assess for opioid‐induced bowel dysfunction (OIBD) in people with cancer and people receiving palliative care the effectiveness and safety of mu‐opioid antagonists (MOAs) versus different doses of MOAs, alternative pharmacological/non‐pharmacological interventions, placebo, or no treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006332-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006332-sec-0015"></div> <section id="CD006332-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006332-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised trials are the best design to minimise bias when evaluating the effectiveness of an intervention. We included double‐blind, randomised controlled trials (RCTs) evaluating the effectiveness of MOAs, compared to a different MOA or at different doses, an alternative pharmacological or non‐pharmacological intervention, a placebo, or no treatment, for OIBD. We did not include open‐label extension phases (where both the researchers and participants know whether they are in the intervention trial arm or the comparison arm) of trials or post‐hoc analyses of trials because they are at an increased risk of bias. No language restrictions were applied. If there was no full journal publication of the trial, we included a published abstract of the trial's final results if it was of sufficient detail to be able to assess risk of bias. For additional data of any included trials we also sought to identify regulatory (e.g. European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency in Japan) assessments of the manufacturer's trial data from Clinical Study Reports.  </p> </section> <section id="CD006332-sec-0018"> <h4 class="title">Types of participants</h4> <p>Eligible trials concerned participants of any age or either sex who were:</p> <p> <ul id="CD006332-list-0001"> <li> <p>people with cancer or people at a palliative stage irrespective of disease, or both;</p> </li> <li> <p>all or the majority (over 95%) were on a stable opioid regimen and had OIBD that had not resolved from taking laxatives. </p> </li> </ul> </p> <p>We included trials of populations of participants where not all fitted our eligibility criteria so long as at least 50% of the sample were people with cancer or people receiving palliative care or at an advanced stage of their disease or where they provided subgroup analysis in either of these participant groups. </p> <p>We did not include trials if the MOAs for bowel dysfunction were for associated postoperative ileus (arrest of intestinal peristalsis). This is because this is not caused primarily by opioids (<a href="./references#CD006332-bbs2-0057" title="MardersteinEL , DelaneyCP . Management of postoperative ileus: focus on alvimopan. Therapeutics and Clinical Risk Management2008;4:965-73.">Marderstein 2008</a>). We excluded trials of healthy volunteers, participants with constipation because of drug misuse, and participants with constipation arising from bowel obstruction were excluded. </p> </section> <section id="CD006332-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials of interventions evaluating a MOA that were either peripherally or systemically acting, and administered at any dose and by any route. These included, for example, methylnaltrexone and naloxone. We included interventions of a MOA if they were evaluated alone or in combination with another drug, for example naloxone in combination with oxycodone. </p> <p>Our comparator interventions of interest were a different MOA, MOA at different doses, an alternative pharmacological or non‐pharmacological intervention, a placebo, or no treatment. </p> </section> <section id="CD006332-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We set four types of primary outcomes of interest and nine secondary outcomes.</p> <section id="CD006332-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>Primary outcomes of interest</p> <p>Laxation response:</p> <p>within 24 hours (short term),  2 weeks (medium‐term) and by patient overall assessment of bowel change at the end of the trial: </p> <p> <ul id="CD006332-list-0002"> <li> <p>self/clinician report of number of spontaneous rescue‐free bowel movements (within 24 hours and two weeks, by any scale or measure); </p> </li> <li> <p>patient report change in bowel status measured using for instance the three‐item Bowel Function Index (BFI), where scores above 28.8 indicate constipation, or rating via the Patient Global Impression of Change using for bowel status a single rating system of better, no change or worse (within the duration of the trial). </p> </li> </ul> </p> <p>Effect on analgesia: within 24 hours and two weeks, by any scale or measure:</p> <p> <ul id="CD006332-list-0003"> <li> <p>symptoms of opioid withdrawal such as sweating, tremor, restlessness and anxiety. This could be measured using for instance the Clinical Opioid Withdrawal Scale (COWS), where a total score of greater than five is considered elevated and clinically significant; </p> </li> <li> <p>change in analgesic requirements such as a 10% increase in requirements;</p> </li> <li> <p>intensity of pain however measured.</p> </li> </ul> </p> <p>Serious adverse events as defined by trial authors.</p> <p> <ul id="CD006332-list-0004"> <li> <p>number and type of adverse event.</p> </li> </ul> </p> <p>The short‐term time point of interest is the first measurement within 24 hours post intervention treatment. This will be taken as within 24 hours of first treatment unless stated otherwise. For medium term this is the first measurement taken between day one and two weeks of intervention treatment. For serious adverse events and adverse events  the time point of interest was the duration of the trial. </p> </section> <section id="CD006332-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>Number of participants who dropped out due to adverse events.</p> <p>Other measures of laxation response: by any scale or measure:</p> <p> <ul id="CD006332-list-0005"> <li> <p>complete evacuation within 24 hours and 2 weeks;</p> </li> <li> <p>not straining within 24 hours and 2 weeks;</p> </li> <li> <p>overall symptoms of constipation in the longer term (beyond two weeks).</p> </li> </ul> </p> <p>Relief of other constipation‐associated symptoms: by any scale or measure:</p> <p> <ul id="CD006332-list-0006"> <li> <p>abdominal cramping;</p> </li> <li> <p>acid reflux;</p> </li> <li> <p>bloating;</p> </li> <li> <p>decreased appetite;</p> </li> <li> <p>difficulty breathing because of pressure in the abdomen;</p> </li> <li> <p>discomfort/pain in the abdomen;</p> </li> <li> <p>hard stools;</p> </li> <li> <p>inability to pass stool when feeling the urge;</p> </li> <li> <p>nausea and vomiting;</p> </li> <li> <p>passing gas.</p> </li> </ul> </p> <p>Use of rescue medication for laxation.</p> <p>Quality of life within 24 hours and two weeks: by a validated scale such as the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire‐C30 (EORTC QLQ‐C30). </p> <p>Participant satisfaction with bowel movements.</p> <p>Participant preference on bowel treatment.</p> <p>Unless stated otherwise, our time points of interest were for outcomes over the duration of the trial. </p> <p>For any primary or secondary outcome, if a trial used several measurements, we selected in order of priority the: </p> <p> <ul id="CD006332-list-0007"> <li> <p>overall total score or global measure;</p> </li> <li> <p>one deemed by the authors as the primary measure;</p> </li> <li> <p>measure the sample size calculation was based on;</p> </li> <li> <p>measure with the median effect. If there was an even number of outcomes, then we selected the more conservative median effect. </p> </li> </ul> </p> </section> </section> </section> <section id="CD006332-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006332-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched five databases. </p> <p> <ul id="CD006332-list-0008"> <li> <p>CENTRAL (Cochrane Library) Issue 12 of 12 2021 (searched from August 2017 to December 2021). </p> </li> <li> <p>MEDLINE and MEDLINE in process (Ovid) August 2017 to 17 December 2021.</p> </li> <li> <p>Embase (Ovid) August 2017 to 17 December 2021.</p> </li> <li> <p>CINAHL (EBSCO) August 2017 to December 2021.</p> </li> <li> <p>Web of Science (SCI‐Expanded and CPCI‐S) August 2017 to 18 December 2021.</p> </li> </ul> </p> <p>The search strategies are listed in <a href="./appendices#CD006332-sec-0146">Appendix 1</a>. </p> </section> <section id="CD006332-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched two clinical trials registries to October 2020 that were not available via CENTRAL: </p> <p> <ul id="CD006332-list-0009"> <li> <p>ISRCTN: <a href="https://www.isrctn.com/" target="_blank">https://www.isrctn.com/</a>; </p> </li> <li> <p>EU Clinical Trials Register (EU‐CTR): <a href="https://www.clinicaltrialsregister.eu/" target="_blank">https://www.clinicaltrialsregister.eu/</a>. </p> </li> </ul> </p> <p>We searched Clinicaltrials.gov and ICTRP via CENTRAL. </p> <p>We searched for any included trials for drug reports from three regulatory agency websites to October 2020: </p> <p> <ul id="CD006332-list-0010"> <li> <p>US Food and Drug Administration (FDA);</p> </li> <li> <p>European Medicines Agency (EMA);</p> </li> <li> <p>Japanese Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau (JPMA). </p> </li> </ul> </p> <p>We searched two pharmaceutical company trials registers:</p> <p> <ul id="CD006332-list-0011"> <li> <p>AstraZeneca Clinical Trials (<a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>); </p> </li> <li> <p>GlaxoSmithKline Clinical Trial Register (<a href="http://www.gsk-clinicalstudyregister.com" target="_blank">www.gsk-clinicalstudyregister.com</a>); </p> </li> </ul> </p> <p>We checked references lists of included trials and any identified systematic reviews. We also undertook a forward citation search of all included trials. We checked conference proceedings of the National Cancer Research Institute (NCRI) Cancer Conference and the European Association of Palliative Care (EAPC) to October 2020. We contacted authors of any identified relevant conference abstracts to ask for full details of their trials. </p> <p>We wrote to pharmaceutical companies that are known manufacturers of MOAs to obtain any trial data not available in peer‐review publications; these were AstraZeneca, Mundipharma GmbH, Progenics, Shionogi, and Valeant. For this purpose, we adapted a letter developed by authors of a previous Cochrane Review; see <a href="./appendices#CD006332-sec-0147">Appendix 2</a> for a copy of this letter. </p> </section> </section> <section id="CD006332-sec-0026"> <h3 class="title" id="CD006332-sec-0026">Data collection and analysis</h3> <section id="CD006332-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BC, LJ) independently screened the citations identified in the database searches. Where it was unclear or likely that the studies fulfilled our inclusion criteria, we retrieved the full‐text articles. If disagreements on eligibility had occurred, we would have resolved them by discussion, or if persistent, by a third review author (PS). If necessary for further clarification such as if it was unclear whether the trial identified was completed and whether their findings were available, we sought contact with the study author or sponsor. </p> </section> <section id="CD006332-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>One review author (BC) extracted data using a standard piloted form and two other review authors checked it for agreement (LJ, VV) before entry into Review Manager [<a href="./references#CD006332-bbs2-0068" title="Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>]. In the event of disagreement, it was planned a third review author (PS) would adjudicate. We collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We collected characteristics of the included studies in sufficient detail to populate a table of 'Characteristics of included studies' in the full review. </p> <p>We extracted the following information.</p> <p> <ul id="CD006332-list-0012"> <li> <p>Study design (including methods, location, funding sources, study author declarations of interest) </p> </li> <li> <p>Setting</p> </li> <li> <p>Participants</p> </li> <li> <p>Intervention(s), Comparator(s), Outcomes (including measures and time points)</p> </li> <li> <p>Numerical data for outcomes of interest</p> </li> </ul> </p> </section> <section id="CD006332-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BC, VV) independently assessed risk of bias for each trial using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD006332-bbs2-0046" title="HigginsJP , AltmanDG , Sterne JA (editors)In: Higgins JP, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.handbook.cochrane.org, 2011.">Higgins 2011</a>), resolving any disagreements by discussion. We completed a risk of bias table for each included trial. We assessed the following. </p> <p> <ul id="CD006332-list-0013"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process: random number table; computer random number generator); and unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process, which were therefore at high risk of bias (odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether the intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively‐numbered, sealed, opaque envelopes); and unclear risk of bias if the method was not clearly stated. We excluded trials that did not conceal allocation, which were therefore at high risk of bias (which may be described as open list or open label). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). The methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved, or it is described as open‐label, but it is not clear what is unmasked). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). The methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study has a clear statement that outcome assessors were unaware of treatment allocation, and ideally describes how this was achieved); unclear risk of bias (study states that outcome assessors were blind to treatment allocation but lacks a clear statement on how it was achieved or it is described as open‐label, but it is not clear what is unmasked). </p> </li> <li> <p>Incomplete outcome data (attrition bias). We assessed whether there was attrition bias due to the amount, nature, or handling of incomplete outcome data. We judged the trial as having low risk of attrition bias if there were no missing outcome data or the reasons for missing data were unlikely to be related to true outcome, or missing data and reasons for it were similar across trial arms, or the missing data had been imputed using appropriate methods. We judged the trial as high risk if the reason for missing outcome data were likely to be related to the outcome, with either imbalance across trial arms in numbers of reasons for missing data and if an inappropriate application of simple imputation was potentially used. We judged the trial as unclear risk if there was insufficient reporting of attrition to permit judgement of low or high risk. </p> </li> <li> <p>Selective outcome reporting (checking if there was a selection of a subset of the original variables recorded on the basis of the results). We assessed selective outcome reporting, if a protocol was available, by comparing outcomes in the protocol and published report. If they were the same we assessed it as low risk in this domain; if they differed, we considered it as high risk. If a protocol was not available, then we compared the outcomes listed in the methods section of an article with the outcomes for which results were reported. If they differed, we considered the trial as high risk. If a protocol was not available and even though the outcomes listed in the methods section and the results section were the same, we considered the trial as having an unclear risk of bias in this domain. Since not all trials have a protocol available, we expected to find a number of trials in this review to be at unclear risk. </p> </li> </ul> </p> </section> <section id="CD006332-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the data using RevMan 5.4 (RevMan 2020). For dichotomous outcomes, we report risk ratios (RRs) and 95% confidence intervals (CIs). For primary outcomes, we calculated numbers needed to treat (NNT) using the 'treat‐as‐one‐trial' method. To indicate direction of effect, we present where appropriate results as either number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH). For continuous outcomes, we report mean differences (MDs) and 95% CIs. If authors reported both change from baseline and post treatment scores, we preferentially reported change from baseline scores. For cross‐over trials, we only generated, as appropriate, a risk ratio (RR) or mean difference (MD) for pre‐cross‐over results. We undertook a meta‐analysis if studies were sufficiently similar in design, population, interventions and outcomes. For trials that used different methods to measure the same continuous outcome, we used standardised mean differences (SMDs) and 95% CsI. </p> </section> <section id="CD006332-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In our handling of each trial analytic, we considered issues that may have impacted on findings. For these we took guidance from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006332-bbs2-0047" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1. Chichester (UK): John Wiley &amp; Sons, 2020.">Higgins 2020</a>). These were: </p> <p> <ul id="CD006332-list-0014"> <li> <p>groups of participants randomised together with the same intervention (e.g. cluster‐randomised trials); </p> </li> <li> <p>participants receiving more than one intervention (e.g. cross‐over trials);</p> </li> <li> <p>multiple observations for the same outcomes (such as repeated measures).</p> </li> </ul> </p> </section> <section id="CD006332-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Given the nature of this field, we anticipated there would be a significant amount of missing data as a result of trial attrition due to the death of the participant. </p> <p>We planned to contact trial authors if we had found data to be missing. For trials using continuous outcomes in which SDs were not reported, and no information was available from the authors, we calculated the SDs using the standard error of the mean (SEM). </p> </section> <section id="CD006332-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity using the I² statistic. The I² statistic is a reliable and robust test to quantify heterogeneity, since it does not depend on the number of trials or on the between‐trial variance. I² measures the extent of inconsistency among trials' results, and can be interpreted as the proportion of total variation in trial estimates that is due to heterogeneity rather than sampling error. We considered an I² value of greater than 50% to indicate substantial heterogeneity and values between 75% to 100% to indicate considerable heterogeneity (<a href="./references#CD006332-bbs2-0047" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1. Chichester (UK): John Wiley &amp; Sons, 2020.">Higgins 2020</a>). Where possible, we planned to undertake sub‐analyses or sensitivity analyses in an attempt to explain heterogeneity. </p> </section> <section id="CD006332-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>To reduce the risk of reporting bias, we undertook comprehensive database and registry searches, including searches of clinical trial registers and drug regulatory agency websites. We also searched websites of, and wrote to, pharmaceutical companies that are known manufacturers of MOAs to identify any further trial data. </p> <p>We planned to assess reporting biases by assessing funnel plots if there were sufficient studies for such an analysis. </p> </section> <section id="CD006332-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Where trial data were sufficiently similar (in diagnostic criteria, intervention, outcome measure, length of follow‐up, and type of analysis), we combined data in a meta‐analysis to provide a pooled effect estimate. We planned to use a fixed‐effect model. For any substantial statistical heterogeneity identified we sought to investigate the extent of heterogeneity. </p> </section> <section id="CD006332-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where heterogeneity was identified in a meta‐analysis, we planned as appropriate subgroup and sensitivity analysis to investigate its possible sources. Subgroup analysis explores whether the overall effect varied with different trial populations, and with the nature and content of the interventions. We planned the following subgroup analysis by excluding studies where not all participants had (1) cancer and/or (2) were receiving palliative care or being at an advanced stage of their disease. </p> </section> <section id="CD006332-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>If sufficient trials were available, we planned to perform, in a meta‐analysis, sensitivity analyses to explore the influence of: </p> <p> <ul id="CD006332-list-0015"> <li> <p>trial quality by excluding trials that had a high risk of bias in any domain;</p> </li> <li> <p>outcomes measured validated tools by excluding trials that did not use validated tools.</p> </li> </ul> </p> </section> <section id="CD006332-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (BC, VV) independently rated the certainty of the body of evidence for the primary outcomes. We used the GRADE system to rank the certainty of the evidence using the guidelines provided in Chapter 14 of the <i>CochraneHandbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006332-bbs2-0047" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1. Chichester (UK): John Wiley &amp; Sons, 2020.">Higgins 2020</a>), GRADEpro Handbook (<a href="./references#CD006332-bbs2-0070" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. GRADE Working Group. (accessed 29/1/21): gdt.guidelinedevelopment.org/app/handbook/handbook.html, 2013.">Schunemann 2013</a>) and GRADE method papers (<a href="./references#CD006332-bbs2-0044" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the evidence--imprecision. Journal of Clinical Epidemiology2011;64:1283-93.">Guyatt 2011</a>; <a href="./references#CD006332-bbs2-0045" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66:151-7.">Guyatt 2013a</a>). </p> <p>The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence. </p> <p> <ul id="CD006332-list-0016"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>The GRADE system considers study design as a marker of quality. Randomised controlled trials are considered to be high quality of evidence and can be downgraded for important limitations. </p> <p>Factors that may decrease the certainty level of a body of evidence are as follows.</p> <p> <ul id="CD006332-list-0017"> <li> <p>Serious or very serious study limitations (risk of bias)</p> </li> <li> <p>Important or serious inconsistency of results</p> </li> <li> <p>Some or major indirectness of evidence</p> </li> <li> <p>Serious or very serious imprecision</p> </li> </ul> </p> <p>We included six summary of findings tables to present the main findings for mu‐opioid antagonists compared to placebo or at a different dose in a transparent and simple tabular format. In particular, we included key information concerning the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes laxation response in the short and medium terms, patient assessment of bowel change and effect on pain, specifically opioid withdrawal symptoms in the medium‐term, adverse and serious adverse events. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006332-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006332-sec-0039"></div> <section id="CD006332-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007407.pub4/references#CD007407-sec-0114" target="_blank">Characteristics of included studies</a>; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007407.pub4/references#CD007407-sec-0115" target="_blank">Characteristics of excluded studies</a>. </p> <section id="CD006332-sec-0041"> <h4 class="title">Results of the search</h4> <p>In this update, we identified 296 unique citations. See <a href="#CD006332-fig-0001">Figure 1</a> for the flowchart of the screening process. We identified two new trials (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>), adding these to those included in the last version resulted in a total of 10 included trials with 1343 participants (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). </p> <div class="figure" id="CD006332-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006332-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>For five included trials we identified regulatory assessments undertaken by theEuropean Medicines Agency (EMA), and the US Food and Drug Administration (FDA) , and the Pharmaceuticals and Medical Devices Agency in Japan of the manufacturers' Clinical Study Reports (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Only one of the regulatory assessments provided additional data, this was for use of rescue medication (<a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). We identified two regulatory reports, but they did not provide any additional data; they are referenced under <a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a> for oxycodone + naloxone, and <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a> for methylnaltrexone. </p> </section> <section id="CD006332-sec-0042"> <h4 class="title">Included studies</h4> <p>All trials were multi‐centre parallel randomised controlled trials (RCTs), except one which was a single‐centre cross‐over RCT (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). Eight trials had sponsorship from a pharmaceutical company (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Two trials involved research sites in multiple countries. In one this included sites in Australia, Czech Republic, France, Germany, Hungary, Israel, the Netherlands, Poland, and the UK (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>), and in the other France, Germany, Poland, and the UK (<a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). In the other trials, populations were from North America (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>), Japan (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>), South Korea (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>), and the UK (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). Four trials had multiple community and hospital care settings including inpatients and outpatients of a hospice or hospital, and long‐term care facilities (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Three were based in the community (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). The other three did not report the setting (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). </p> <p>In all trials the majority of participants had a primary diagnosis of cancer. Four trials included participants with chronic cancer pain who were not described as being at an advanced disease stage (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). The six other trials evaluated effects in participants with an advanced disease including cancer, and other conditions such as AIDS or circulatory disease. Where reported, authors described what they meant by advanced disease by using general terms such as terminal, end‐stage, or metastatic cancer. Nine of the trials excluded patients in situations that may affect efficacy of trial by compounding constipation such as any disease processes suggestive of abnormalities of the gastrointestinal tract, or the use of chemotherapy. In the other trial this is not stated in the exclusion criteria but the investigators ‘confirmed prior to inclusion that the constipation was caused or aggravated by opioid use' (<a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>).  </p> <p>All participants were adults. At baseline all participants were on a stable opioid regimen, and had opioid‐induced bowel dysfunction (OIBD).  Eight trials specified that the indication for opioids was pain (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). The other two trials did not state the indication (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). Nine  trials reported that all or the majority (90% or greater) of participants were taking regular laxatives. In the 10th trial, patients were not eligible if they had been taking regular laxatives for one or more weeks before screening (<a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> <p>Three trials had multiple trial arms (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>), the others were two‐armed. The mu‐opioid antagonists (MOAs) were either compared with a placebo or with the MOA administered either at different doses or in combination with other drugs. In four trials, the MOA was subcutaneous methylnaltrexone (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Four other trials tested oral naloxone; in one naloxone only (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>), and in three oxycodone (an opioid) in combination with naloxone (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). The other two trials evaluated oral naldemedine (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). We identified no trials that evaluated naloxegol or other MOAs. </p> <p>Laxation response was measured in eight trials as self, carer or clinician report (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>; <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Two trials measured response using the Bowel Function Index (BFI) (three items, the lower the score the better bowel function) (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). Effect on analgesia was measured either using self‐rated pain scores or symptoms of opioid withdrawal. To measure symptoms of opioid withdrawal, three trials used the modified Himmelsbach withdrawal scale (seven items; higher scores indicating greater severity) (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>), and two the Clinical Opioid Withdrawal Scale (COWS) (11 items, higher scores indicating more symptoms and severity. A score greater than 36 indicates severe withdrawal) (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). All trials reported the incidence of serious adverse events.  </p> <p>Further details of these trials including MOAs dose and schedule, and study funding source are shown in the <a href="./references#CD006332-sec-0165" title="">Characteristics of included studies</a> tables. </p> <section id="CD006332-sec-0043"> <h5 class="title">Ongoing studies and studies awaiting classification</h5> <p>We identified four trials whose results are yet to be published, of these two are evaluating methylnaltrexone (<a href="./references#CD006332-bbs2-0026" title="NeefjesEC , van derVorstMJ , BoddaertMS , ZuurmondWW , van derVlietHJ , BeekerA , et al. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care2014;13:42. ">Neefjes 2014</a>; <a href="./references#CD006332-bbs2-0027" title="PeppinJ . RCT: methylnaltrexone in patients with advanced illness with opioid induced constipation. Journal of Pain2013;14:S62. ">Peppin 2013</a>), one naloxegol (<a href="./references#CD006332-bbs2-0025" title="GuptaP . Naloxegol in treating patients with stage IIIB-IV non-small cell lung cancer. ClinicalTrials.gov2017. ">NCT03067708</a>), and one oxycodone/naloxone (<a href="./references#CD006332-bbs2-0028" title="WongA . A multi-centre, randomised, phase IV study to compare the efficacy of oxycodone/naloxone verses oxycodone prolonged release tablets in patients with advanced cancer ACTRN12619001282178. ANZCTR2019. ">Wong 2019</a>). We identified six for which we are awaiting classification on their eligibility; this is mainly as we have insufficient details on study population. Further details of these are in the <a href="./references#CD006332-sec-0168" title="">Characteristics of ongoing studies</a> and <a href="./references#CD006332-sec-0167" title="">Characteristics of studies awaiting classification</a>, respectively. </p> </section> </section> <section id="CD006332-sec-0044"> <h4 class="title">Excluded studies</h4> <p>We excluded eight trials, three because they did not include participants with cancer or at the palliative stage of a disease, three as they were not RCTs, and two as the interventions were preventive. These trials are listed in the <a href="./references#CD006332-sec-0166" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD006332-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>All trials were vulnerable to a number of biases, most commonly this included an unclear risk of detection bias. See <a href="#CD006332-fig-0002">Figure 2</a>; <a href="#CD006332-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006332-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006332-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006332-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006332-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006332-sec-0046"> <h4 class="title">Allocation</h4> <section id="CD006332-sec-0047"> <h5 class="title">Random sequence generation</h5> <p>The method of randomisation sequence generation was described adequately in six trials (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>), and we judged them to be at low risk of bias. In four trials the risk of bias was unclear as they did not provide any details. </p> </section> <section id="CD006332-sec-0048"> <h5 class="title">Allocation concealment</h5> <p>Three trials adequately described allocation concealment (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). In seven trials the risk of bias was unclear as they did not provide any details. </p> </section> </section> <section id="CD006332-sec-0049"> <h4 class="title">Blinding</h4> <section id="CD006332-sec-0050"> <h5 class="title">Performance bias</h5> <p>Four trials were at a low risk of performance bias (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). In six trials this was unclear as they did not provide any details. </p> </section> <section id="CD006332-sec-0051"> <h5 class="title">Detection bias</h5> <p>Two trials were at a low risk of detection bias (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). In eight trials it was unclear as they did not provide any details. </p> </section> </section> <section id="CD006332-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias was low in eight trials. In one trial it was high risk as attrition was unbalanced between the trial arms with more leaving because of adverse events in the intervention arm (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). In another trial risk was unclear as it was not stated how many had dropped out of the subgroup of people with cancer (<a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). </p> </section> <section id="CD006332-sec-0053"> <h4 class="title">Selective reporting</h4> <p>The risk of selective reporting was unclear in five trials as there were no published protocols to check.The other five were low risk of bias as they had a protocol and whose report on outcome measurements was consistent with those in the published results paper (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> </section> <section id="CD006332-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>None of serious concern.</p> </section> </section> <section id="CD006332-sec-0055"> <h3 class="title" id="CD006332-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD006332-tbl-0001"><b>Summary of findings 1</b> Naldemedine compared to placebo for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</a>; <a href="./full#CD006332-tbl-0002"><b>Summary of findings 2</b> Low dose naldemedine compared to higher doses for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</a>; <a href="./full#CD006332-tbl-0003"><b>Summary of findings 3</b> Naloxone compared with placebo for opioid‐induced bowel dysfunction in people with cancer and receiving palliative care</a>; <a href="./full#CD006332-tbl-0004"><b>Summary of findings 4</b> Naloxone + oxycodone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</a>; <a href="./full#CD006332-tbl-0005"><b>Summary of findings 5</b> Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</a>; <a href="./full#CD006332-tbl-0006"><b>Summary of findings 6</b> Methylnaltrexone lower dose compared to higher dose for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</a> </p> <p>The trials varied in mu‐opioid antagonists (MOA) evaluated and comparison, and how they reported the outcomes. This limited the number of combined analyses. </p> <section id="CD006332-sec-0056"> <h4 class="title">Naldemedine versus placebo</h4> <p>Two trials (418 participants) of people with cancer irrespective of disease stage evaluated the effectiveness of two weeks of oral treatment with naldemedine compared to placebo (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). In one trial the oral doses of naldemedine were per arm 0.1 mg, 0.2 mg or 0.4 mg daily for two weeks (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>), and in the other 0.2 mg daily for two weeks (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <section id="CD006332-sec-0057"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD006332-tbl-0001">summary of findings Table 1</a> for this comparison. </p> <section id="CD006332-sec-0058"> <h6 class="title">Laxation response</h6> <p>Response in the short term was not reported. Two trials (418 participants) reported response in the medium term (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). The risk (i.e. chance) of spontaneous laxations over two weeks in those taking naldemedine was more than three times the risk for those taking placebo (risk ratio (RR) 2.00, 95% confidence interval (CI) 1.59 to 2.52, 2 trials, 418 participants, I² = 0%; number needed to treat for an additional beneficial outcome (NNTB) 3, 95% CI 3 to 4. <a href="./references#CD006332-fig-0004" title="">Analysis 1.1</a>. <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). We judged the certainty of evidence for laxation response within two weeks to be moderate. We downgraded evidence by one level for serious limitations to the study design as one study had a high risk of attrition bias. </p> <p>Patient assessment of change in bowel status was not reported.</p> </section> <section id="CD006332-sec-0059"> <h6 class="title">Effect on analgesia</h6> <p>Short term effect on analgesia was not reported. Only one trial (112 participants) reported on opioid withdrawal symptoms in the medium term (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>Naldemedine may have little to no effect on opioid withdrawal symptoms compared to placebo in the medium term (over two weeks since first dose) (naldemedine 0.1 mg: mean difference (MD) ‐0.10, 95% CI ‐0.56 to 0.36, 1 trial, 112 participants. <a href="./references#CD006332-fig-0005" title="">Analysis 1.2</a>; naldemedine 0.2 mg: MD 0.30, 95% CI ‐0.21 to 0.81, 1 trial, 114 participants. <a href="./references#CD006332-fig-0006" title="">Analysis 1.3</a>; naldemedine 0.4 mg: MD 0.20, 95% CI ‐0.36 to 0.76, 1 trial, 112 participants. <a href="./references#CD006332-fig-0007" title="">Analysis 1.4</a>. <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). We judged the certainty of evidence as very low. We downgraded the certainty of evidence by two levels for very serious limitations to the study design as data derived from only one study with a high risk of attrition bias and one level because of serious imprecision as data were derived from fewer than 400 participants. </p> <p>Change in analgesic requirements and pain intensity were not reported.</p> </section> <section id="CD006332-sec-0060"> <h6 class="title">Serious adverse events </h6> <p>Two trials (418 participants) reported serious adverse events over course of follow‐up (to two weeks in <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; to six weeks in <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>Naldemedine may have little to no impact on the risk of non‐fatal serious adverse events compared to placebo (RR 3.34, 95% CI 0.85 to 13.15, 2 trials, 418 participants, I² = 0%. <a href="./references#CD006332-fig-0008" title="">Analysis 1.5</a>. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). Eleven non‐fatal serious adverse events occurred in the naldemedine arms. In one trial four of the seven non‐fatal serious adverse events in the naldemedine arm were considered to be related to the study drug, these were two cases of diarrhoea, one case of vomiting and one abnormal hepatic function test (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). In the other trial there were in the naldemedine arm one case of each of gastro‐intestinal haemorrhage, pneumonia, anaemia and asthenia, the investigators do not state whether they considered these events related to the study drug (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). One death occurred in one trial (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>), and two in the other (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). All three occurred in the naldemedine trial arms, the deaths were not considered to be related to naldemedine. We judged the certainty of evidence on risk of non‐fatal serious adverse events as low. We downgraded the certainty of evidence by two levels, one for serious limitations to the study design (in one study there was a high risk of attrition bias) and one level for serious imprecision (wide confidence intervals). </p> </section> <section id="CD006332-sec-0061"> <h6 class="title">Number and type of adverse events </h6> <p>Two trials (418 participants) reported number and type of adverse event over course of follow‐up (to two weeks in <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; to six weeks in <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>There was over double the risk of adverse events reported in naldemedine arms compared to placebo arms (RR 1.49, 95% CI 1.19 to 1.87, 2 trials, 418 participants, I² = 0%. <a href="./references#CD006332-fig-0009" title="">Analysis 1.6</a>. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). We judged the certainty of evidence as moderate. We downgraded the certainty of evidence by one level for serious limitations to the study design (in one study there was a high risk of attrition bias). </p> <p>The most common adverse event in both trials was diarrhoea. There was four times the risk of diarrhoea in naldemedine arms compared to placebo arms (RR 1.85, 95% CI 1.22 to 2.82, 2 trials, 419 participants, I² = 17%. <a href="./references#CD006332-fig-0010" title="">Analysis 1.7</a>. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> </section> </section> <section id="CD006332-sec-0062"> <h5 class="title">Secondary outcomes</h5> <section id="CD006332-sec-0063"> <h6 class="title">Number who dropped out due to adverse events </h6> <p>Outcome reported in two trials over the course of follow‐up (to two weeks in <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>; to six weeks in <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>The risk of drop out of the study due to adverse events was over eight‐times greater in the naldemedine arms compared to placebo arms (RR 5.18, 95% CI 1.28 to 20.91, 2 trials, 420 participants, I² = 0%. <a href="./references#CD006332-fig-0011" title="">Analysis 1.8</a>. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>; <a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> </section> <section id="CD006332-sec-0064"> <h6 class="title">Other measures of laxation responses </h6> <p>Only one trial (193 participants) reported this outcome (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>There were more spontaneous laxations that felt like a complete evacuation in the naldemedine arm compared to placebo arm (MD 2.05, 95% CI 1.29 to 2.81, 1 trial, 193 participants, full data not provided. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). There were more spontaneous laxations without straining in the naldemedine arm compared to placebo arm (MD 2.67, 95% CI 1.20 to 4.15, 1 trial, 193 participants, full data not provided. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> </section> <section id="CD006332-sec-0065"> <h6 class="title">Relief of other constipation‐associated symptoms </h6> <p>Only one trial (193 participants) reported this outcome (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>There was little to no difference in overall relief of symptoms (e.g. bloating, abdomen discomfort or pain) between the naldemedine arm and placebo arm at two weeks (mean change ‐0.25 naldemedine, mean change ‐0.18 placebo, P value = not significant, 1 trial, 193 participants. Full data not provided. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> </section> <section id="CD006332-sec-0066"> <h6 class="title">Quality of life </h6> <p>Only one trial (193 participants) reported this outcome (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>There was little to no difference in quality of life between the naldemedine arm and placebo arm at two weeks (mean change ‐0.25 naldemedine, mean change‐0.15 placebo, P value = 0.08, 1 trial, 193 participants. Full data not provided. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> </section> <section id="CD006332-sec-0067"> <h6 class="title">Satisfaction with bowel movements </h6> <p>Only one trial (193 participants) reported this outcome (<a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> <p>There was less dissatisfaction with bowel movements in the naldemedine arm compared with placebo arm at two weeks (mean change ‐0.50 naldemedine arm, mean change ‐0.16 placebo arm, P value = 0.015, 1 trial, 193 participants. Full data not provided. <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). </p> </section> <section id="CD006332-sec-0068"> <h6 class="title">Use of rescue medication for laxation over course of trial, and participant preference</h6> <p>These outcomes were not reported.</p> </section> </section> </section> <section id="CD006332-sec-0069"> <h4 class="title">Low dose naldemedine versus higher dose naldemedine</h4> <p>Only one trial (225 participants) evaluated the effectiveness of two weeks of oral treatment with naldemedine at different doses, 0.1 mg, 0.2 mg, or 0.4 mg daily, in people with cancer irrespective of disease stage (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <section id="CD006332-sec-0070"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD006332-tbl-0002">summary of findings Table 2</a> for primary outcomes. </p> <section id="CD006332-sec-0071"> <h6 class="title">Laxation response</h6> <p>Laxation response was not reported in the short term. The trial (225 participants) reported the outcome in the medium term (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>There were fewer spontaneous laxations in the naldemedine 0.1 mg arm compared with higher dose arms of naldemedine 0.2 mg and 0.4 mg over two weeks ( 0.1 mg versus 0.4 mg: RR 0.69, 95% CI 0.53 to 0.89 1 trial, 111 participants. <a href="./references#CD006332-fig-0012" title="">Analysis 2.1</a>; 0.1 mg versus 0.2 mg: RR 0.73, 95% CI 0.55 to 0.95, 1 trial, 113 participants. <a href="./references#CD006332-fig-0013" title="">Analysis 2.2</a>). There was little to no difference in risk of spontaneous laxations between naldemedine 0.2 mg arm compared to naldemedine 0.4 mg arm (RR 0.94, 95% CI 0.79 to 1.14, 114 participants. <a href="./references#CD006332-fig-0014" title="">Analysis 2.3</a>). We judged the certainty of evidence on laxation response as low. We reduced it by one level because of serious study limitations because of unclear risk of bias (reporting bias) and one level because of serious imprecision (data derived from fewer than 400 participants). </p> <p>Patient assessment of change in bowel status was not reported.</p> </section> <section id="CD006332-sec-0072"> <h6 class="title">Effect on analgesia</h6> <p>Effect in short term was not reported. The trial (225 participants) reported opioid withdrawal symptoms in the medium term (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>There was little to no difference on opioid withdrawal symptoms between the three naldemedine dose arms (0.1 mg versus 0.2 mg. MD ‐0.40, 95% CI ‐0.90 to 0.10, 114 participants. <a href="./references#CD006332-fig-0016" title="">Analysis 2.5</a>; 0.1 mg versus 0.4 mg MD ‐0.30, 95% CI ‐0.85 to 0.25, 112 participants. <a href="./references#CD006332-fig-0015" title="">Analysis 2.4</a>;  0.2 mg versus 0.4 mg: MD 0.10, 95% CI ‐0.49 to 0.69, 114 participants.<a href="./references#CD006332-fig-0017" title="">Analysis 2.6</a>).  We judged the certainty of evidence for effect on analgesia (opioid withdrawal) to be low. We downgraded the certainty of evidence by one level for serious limitations to the study design unclear risk of bias (reporting bias) and imprecision (data derived from fewer than 400 participants).  </p> <p>Change in analgesic requirements and pain intensity were not reported.</p> </section> <section id="CD006332-sec-0073"> <h6 class="title">Serious adverse events </h6> <p>One trial (225 participants) reported this outcome (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>There was little to no difference in occurrence of serious adverse events between the dose arms (0.1 mg versus 0.4 mg RR 0.25, 95% CI 0.03 to 2.17, 112 participants (<a href="./references#CD006332-fig-0021" title="">Analysis 2.10</a>). There were five serious adverse events. Four of the events occurred in the highest dose arm (naldemedine 0.4 mg). One participant each experienced pneumonia, anaemia, or asthenia. One participant died due to bile duct cancer. The other participant experienced a gastrointestinal bleed (taking naldemedine 0.1 mg). The investigators considered the death unrelated to the study drug. Judgements on whether the other events were related to the study drug were not reported. We judged the certainty of evidence for serious adverse events to be low. We downgraded the certainty of evidence by two levels, one for serious limitations to the study design and one for serious imprecision. This was because of unclear risk of bias (reporting bias) and a limited number of events. </p> </section> <section id="CD006332-sec-0074"> <h6 class="title">Number and type of adverse events </h6> <p>The trial (225 participants) reported these outcomes (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>There was little to no difference in the occurrence of an adverse event between the three naldemedine dose arms (0.1 mg versus 0.4 mg RR 0.84, 95% CI 0.67 to 1.06, 1 trial, 112 participants. <a href="./references#CD006332-fig-0018" title="">Analysis 2.7</a>; 0.1 mg versus 0.2 mg RR 0.98, 95% CI 0.76 to 1.27, 1 trial, 114 participants <a href="./references#CD006332-fig-0019" title="">Analysis 2.8</a>; 0.2 mg versus 0.4 mg RR 0.86, 95% CI 0.68 to 1.07, 1 trial, 114 participants. <a href="./references#CD006332-fig-0020" title="">Analysis 2.9</a>). We judged the certainty of evidence on risk of an adverse event to be low. We downgraded the certainty of evidence by one level for serious limitations to the study design and one level for serious imprecision. This was because of unclear risk of bias (reporting bias) and data derived from fewer than 400 participants). </p> <p>The most common adverse event was diarrhoea. There were fewer events of diarrhoea in the naldemedine 0.1 mg arm compared with the naldemedine 0.4 mg arm (RR 0.61, 95% CI 0.40 to 0.95, 1 trial, 112 participants. <a href="./references#CD006332-fig-0022" title="">Analysis 2.11</a>). There was little to no difference in the proportion experiencing diarrhoea between naldemedine 0.1 mg arm and naldemedine 0.2 mg arm (RR 0.73, 95% CI 0.46 to 1.15, 1 trial, 114 participants. <a href="./references#CD006332-fig-0023" title="">Analysis 2.12</a>) and between 0.2 mg naldemedine arm and 0.4 mg naldemedine arm (RR 0.84, 95% CI 0.59 to 1.21, 1 trial, 114 participants. <a href="./references#CD006332-fig-0024" title="">Analysis 2.13</a>). </p> </section> </section> <section id="CD006332-sec-0075"> <h5 class="title">Secondary outcomes</h5> <section id="CD006332-sec-0076"> <h6 class="title">Number who dropped out due to adverse events </h6> <p>The trial (225 participants) reported this outcome (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>There was little to no difference in the proportion of participants who dropped out of the study due to adverse events between naldemedine dose arms (e.g. 0.1 mg versus 0.4 mg MD 0.75, 95% CI 0.18 to 3.20, 1 trial, 112 participants <a href="./references#CD006332-fig-0025" title="">Analysis 2.14</a>; <a href="./references#CD006332-fig-0026" title="">Analysis 2.15</a>; <a href="./references#CD006332-fig-0027" title="">Analysis 2.16</a>). </p> </section> <section id="CD006332-sec-0077"> <h6 class="title">Other measures of laxation response </h6> <p>The trial (225 participants) reported this outcome (<a href="./references#CD006332-bbs2-0004" title="KatakamiN , OdaK , TauchiK , NakataK , ShinozakiK , YokotaT , et al. Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. Journal of Clinical Oncology2017;35:1921-8. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21)2017. ">Katakami 2017a</a>). </p> <p>There was a lower frequency of spontaneous laxations without straining in the naldemedine 0.4 mg arm compared with either of the two arms of naldemedine at lower doses (0.2 mg P value 0.04; 0.1 mg P value = &lt; 0.001, full data not provided). There was little to no difference in the frequency without straining of spontaneous laxations between naldemedine 0.1 mg and 0.2 mg (P value = 0.16, full data not provided). There was a greater feeling of complete evacuation in naldemedine arms 0.4 mg (P value = &lt; 0.001) and 0.2 mg (P value = 0.04) arms compared to naldemedine 0.1 mg arm (full data not provided). There was little to no difference in the feeling of complete evacuation between naldemedine arms taking either 0.4 mg or 0.2 mg (P value = 0.12, full data not provided). </p> </section> <section id="CD006332-sec-0078"> <h6 class="title">Other secondary outcomes</h6> <p>Relief of other constipation‐associated symptoms, use of rescue medication for laxation, satisfaction with bowel movements, quality of life, and participant preference were not reported. </p> </section> </section> </section> <section id="CD006332-sec-0079"> <h4 class="title">Naloxone versus placebo</h4> <p>Only one cross‐over trial (17 participants) evaluated the effectiveness of oral naloxone compared with placebo in people with advanced cancer (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). The participants received two days of either placebo or naloxone followed by another two days on the trial agent that was not received on day one and two. This was without washout, as in there was no treatment phase designed to reduce biased results by separating the two treatment phases of the trial to eliminate 'carry‐over' effects from the first trial drug, placebo or naloxone.  Naloxone was given four‐hourly for a total daily dose of 0.5%, 1%, 2%, 5%, 10%, or 20% of the total daily dose of morphine. </p> <section id="CD006332-sec-0080"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD006332-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD006332-sec-0081"> <h6 class="title">Laxation response</h6> <p>This outcome was not reported.</p> </section> <section id="CD006332-sec-0082"> <h6 class="title">Effect on analgesia</h6> <p>The trial (17 participants) reported in the medium term opioid withdrawal symptoms and pain intensity (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). There was little to no difference in pain intensity experienced between when the participants were taking naloxone and placebo. Full data not provided, including pre‐cross‐over results provided. There was insufficient evidence provided to make a GRADE judgement on certainty of evidence.  </p> <p>Change in analgesic requirements was not reported.</p> </section> <section id="CD006332-sec-0083"> <h6 class="title">Serious adverse events </h6> <p>The trial (17 participants) reported on this outcome (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). There were no serious adverse events reported. We judged the certainty of evidence on risk for a serious adverse event to be very low. We downgraded the certainty of evidence on risk by one level for serious limitations to the study design and two levels for very serious imprecision. This was because of unclear risk of bias (reporting bias) and data derived from fewer than 400 participants. </p> </section> <section id="CD006332-sec-0084"> <h6 class="title">Number and type of adverse events</h6> <p>These outcomes were not reported.</p> </section> </section> <section id="CD006332-sec-0085"> <h5 class="title">Secondary outcomes</h5> <section id="CD006332-sec-0086"> <h6 class="title">Number who dropped out due to adverse events </h6> <p>The trial (17 participants) reported this outcome (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>). </p> <p>Four participants dropped out due to adverse events. Two participants withdrew from the study whilst taking naloxone, one because of general deterioration in health while taking naloxone (although not thought to be a causal relationship), and one participant withdrew because of nausea after two doses of naloxone at the 10% level (5 mg in this case).  One participant because of diarrhoea experienced while receiving the placebo. One participant withdrew because of severe diarrhoea caused by the lactulose taken as part of the test on bowel function. </p> </section> <section id="CD006332-sec-0087"> <h6 class="title">Other outcomes</h6> <p>Other measures of laxation response, relief of other constipation‐associated symptoms, use of rescue medication for laxation, quality of life, patient satisfaction with bowel movements, and participant preference were not reported. </p> </section> </section> </section> <section id="CD006332-sec-0088"> <h4 class="title">Naloxone with oxycodone versus oxycodone</h4> <p>Three trials (368 participants) evaluated the effectiveness of oxycodone with naloxone prolonged‐release tablets (OXN PR) compared with oxycodone prolonged‐release (OXY PR) tablets in people with cancer (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). In one trial, participants had cancer at any stage and the drug dose for OXN PR was up to 120 mg daily over four weeks of treatment (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>). In one of the other trials they evaluated five weeks of OXN PR up to 160 mg daily in people with cancer and non‐cancer pain. We included the trial's participant subset data on 46 people with cancer (<a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). The third trial evaluated four weeks of OXN PR up to 80 mg daily in participants with moderate to severe cancer pain (<a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> <section id="CD006332-sec-0089"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD006332-tbl-0004">summary of findings Table 4</a> for primary outcomes. </p> <section id="CD006332-sec-0090"> <h6 class="title">Laxation response</h6> <p>Risk of spontaneous rescue‐free laxations was not reported in the short or medium term. </p> <p>Two trials (212 participants) reported patient assessment of change in bowel status over the course of the trial (at five weeks <a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>, and at four weeks since start of treatment <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). In one trial there was more improvement in bowel status in the OXN PR arm compared to OXY PR arm (mean change – 11.14, 95% CI ‐19.03 to ‐3.24, 1 trial, 133 participants, full data not provided <a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>). In the other there was little to no change in bowel status between trial arms (P value = 0.264, 1 trial, 79 participants, full data not provided <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). We judged the certainty of evidence on patient assessment of change in bowel status as low. We downgraded by one level because of serious limitations to the study design (unclear risk of reporting bias), and one level for serious imprecision (data derived from fewer than 400 participants).  </p> </section> <section id="CD006332-sec-0091"> <h6 class="title">Effect on analgesia</h6> <p>Short‐term effects were not reported. Only one trial (133 participants) reported opioid withdrawal symptoms in the medium term (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>). </p> <p>There was little to no difference in opioid withdrawal symptoms between OXN PR arm and OXY PR arm at one week following end of treatment (MD ‐0.63, 95% CI ‐2.44 to 1.18 , 1 trial, 133 participants. <a href="./references#CD006332-fig-0028" title="">Analysis 3.1</a>). We judged the certainty of evidence on opioid withdrawal symptoms as low.  We downgraded by one level because of serious study limitations (unclear risk of bias reporting bias) and one level for serious imprecision (data derived from fewer than 400 participants). </p> <p>Medium‐term effect on change in analgesic requirements and pain intensity were not reported. </p> </section> <section id="CD006332-sec-0092"> <h6 class="title">Serious adverse events </h6> <p>Three trials (362 participants) reported this outcome (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> <p>There was little to no difference in the proportion of participants experiencing a serious adverse event (SAE) between OXN PR arms and OXY PR arms (RR 0.68, 95% CI 0.44 to 1.06) I² = 55%, 3 trials, 362 participants. <a href="./references#CD006332-fig-0029" title="">Analysis 3.2</a>). We were unable to explore the substantial statistical heterogeneity found as none of the trials fitted our criteria for either subgroup or sensitivity analyses. One trial attributed all 12 events to the study drugs; there were eight events in the OXN PR arm and four in the OXY PR arm (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>). In the other trials, one attributed none of the events to the study drug (<a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>) and the other does not detail whether the events could be attributed to the study drug (<a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). In one trial 18 participants died, nine in each trial arm (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>), in one of the other trials one participant died in the OXN PR arm and three in the OXY PR arm (<a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). None of the deaths were attributed to the trial drugs. The other trial did not report any deaths (<a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). We judged the certainty of evidence of serious adverse events to be very low. We downgraded by one level because of serious study limitations (unclear risk of bias reporting bias), one for serious imprecision (data derived from fewer than 400 participants) and one for serious inconsistency (substantial unexplained heterogeneity). </p> </section> <section id="CD006332-sec-0093"> <h6 class="title">Number and type of adverse events </h6> <p>Three trials (362 participants) reported these outcomes (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> <p>There was little to no difference in the proportion of participants experiencing an adverse event between OXN PR arms and OXY PR arms (RR 1.01; 95% 0.87 to 1.18. I² = 0%; 3 trials, 362 participants. <a href="./references#CD006332-fig-0030" title="">Analysis 3.3</a>). We judged the certainty of evidence for number of adverse events to be low. We downgraded by one level because of serious study limitations (unclear risk of bias reporting bias) and one level for serious imprecision (data derived from fewer than 400 participants). </p> <p>A common adverse event reported in all three trials was nausea. Fewer participants experienced nausea in the OXN PR arms compared with OXY PR arms (RR 0.55, 95% CI 0.33 to 0.94. I² = 0%; 3 trials, 362 participants. <a href="./references#CD006332-fig-0031" title="">Analysis 3.4</a>). </p> </section> </section> <section id="CD006332-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD006332-sec-0095"> <h6 class="title">Number who dropped out due to adverse events </h6> <p>Two trials (312 participants) reported this outcome (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> <p>There was little to no difference in the proportion of participants who dropped out of the study due to adverse events between the OXN PR arm and OXY PR arm (RR 1.25, 95% CI 0.73 to 2.15; 2 trials, 312 participants, I² = 58%, <a href="./references#CD006332-fig-0032" title="">Analysis 3.5</a>. <a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> </section> <section id="CD006332-sec-0096"> <h6 class="title">Use of rescue medication for laxation </h6> <p>Two trials (220 participants) reported this outcome (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). There was little to no difference in the use of rescue medication (oral bisacodyl) between the OXN PR arms and OXY PR arms (SMD ‐0.27, 95% CI ‐0.53 to ‐0.00. 2 trials, 220 participants, I² = 0%. <a href="./references#CD006332-fig-0033" title="">Analysis 3.6</a>. <a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0003" title="DupoironD , StachowiakA , LoewensteinO , ElleryA , KremersW , BosseB , et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR. European Journal of Pain.2017;21:1528-37. ">Dupoiron 2017</a>). </p> </section> <section id="CD006332-sec-0097"> <h6 class="title">Quality of life</h6> <p>Two trials (200 participants) reported this outcome (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). There was little to no difference in quality of life at four weeks between the OXN PR arms and OXY PR arms (SMD 0.08, 95% CI ‐0.20 to 0.35, 2 trials, 200 participants, I² = 0%. <a href="./references#CD006332-fig-0034" title="">Analysis 3.7</a>. <a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0006" title="Lee K-H, Kim TW , Kang J-H, Kim J-S, Ahn J-S, Kim S-Y, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer2017;36:74. ">Lee 2017</a>). </p> </section> <section id="CD006332-sec-0098"> <h6 class="title">Other outcomes</h6> <p>Relief of other constipation‐associated symptoms in the short to medium term, other measures of laxation response, participant satisfaction with bowel movements, and participant preference were not reported. </p> </section> </section> </section> <section id="CD006332-sec-0099"> <h4 class="title">Methylnaltrexone versus placebo</h4> <p>Three trials (518 participants) evaluated the effectiveness of subcutaneous methylnaltrexone compared to placebo in people with advanced disease, of which the majority of participants had cancer (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>).  One trial involved two active treatment arms; a single dose of either methylnaltrexone 0.15 mg/kg or 0.30 mg/kg (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). The other two trials administered methylnaltrexone every other day for two weeks. One trial administered methylnaltrexone 0.15 mg/kg of bodyweight (<a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>), and the other trial, with the aim of improving ease of administration, administered methylnaltrexone 8 mg to participants whose bodyweight was between 38 kg and 62 kg, or methylnaltrexone 12 mg if they weighed more than 62 kg (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>). </p> <section id="CD006332-sec-0100"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD006332-tbl-0005">summary of findings Table 5</a> . </p> <section id="CD006332-sec-0101"> <h6 class="title">Laxation response</h6> <p>Two trials (287 participants) reported short‐term outcome (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). The risk of spontaneous rescue‐free laxations within 24 hours of the first treatment dose was over three times greater in the methylnaltrexone arm compared to the placebo arm (RR 2.97, 95% CI 2.13 to 4.13. 2 trials, 287 participants, I² = 31%. NNTB 3, 95% CI 2 to 3. <a href="./references#CD006332-fig-0035" title="">Analysis 4.1</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). We judged the certainty of evidence for laxation within 24 hours of the first dose to be low. We downgraded by one level for serious study limitations (unclear risk of bias due to reporting bias) and one for serious imprecision (data from fewer than 400 participants). </p> <p>Two trials (305 participants) reported medium‐term outcome. The risk of spontaneous rescue‐free laxations was more than seven times greater in the medium term in the methylnaltrexone arms compared to placebo arms (RR 8.15, 95% CI 4.76 to 13.95, 2 trials, 305 participants, I² = 47%. NNTB 2, 95% CI 2 to 2 <a href="./references#CD006332-fig-0036" title="">Analysis 4.2</a>. <a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). We judged the certainty of evidence for laxation response over two weeks to be moderate. We downgraded by one level for serious study limitations (unclear risk of bias due to reporting bias). As the effect size was large, we did not downgrade for serious imprecision because data were derived from fewer than 400 participants. </p> <p>Two trials report change in patient assessed bowel status over the course of the trial (287 participants) (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Improvement in bowel status was three times greater in patients in the methylnaltrexone arms compared to placebo arms (RR 2.32, 95% CI 1.64 to 3.27, 2 trials, 287 participants. <a href="./references#CD006332-fig-0037" title="">Analysis 4.3</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). We judged the certainty of evidence for patient assessment of change in bowel status to be low. We downgraded by one level for serious study limitations (unclear risk of bias due to reporting bias) and one for serious imprecision (data from fewer than 400 participants). </p> </section> <section id="CD006332-sec-0102"> <h6 class="title">Effect on analgesia</h6> <p>Two trials reported opioid withdrawal symptoms in the short term (287 participants) (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>) and two trials (285 participants) in the medium‐term (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Two trials (285 participants) reported on pain intensity in the short term (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). </p> <p>There was little to no difference in effect on opioid withdrawal symptoms in the short term between methylnaltrexone arms at different doses and placebo arms (at four hours post treatment: methylnaltrexone 0.15 mg/kg MD ‐0.05, 95% CI ‐0.56 to 0.46, 1 trial, 99 participants. <a href="./references#CD006332-fig-0039" title="">Analysis 4.5</a>.  <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; methylnaltrexone 0.30 mg/kg MD ‐0.01, 95% CI ‐0.40 to 0.38, 1 trial, 107 participants. <a href="./references#CD006332-fig-0040" title="">Analysis 4.6</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; in the other trial at 24 hours MD 0.00, 95% CI ‐0.46 to 0.46, 1 trial, 133 participants. <a href="./references#CD006332-fig-0038" title="">Analysis 4.4</a>. <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). </p> <p>There was little to no difference in effect on opioid withdrawal symptoms between methylnaltrexone and placebo in the medium term (MD ‐0.20, 95% CI ‐0.80 to 0.40, 1 trial, 133 participants. <a href="./references#CD006332-fig-0041" title="">Analysis 4.7</a>.  <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>; methylnaltrexone 0.15 mg/kg MD ‐0.40, 95% CI ‐0.90 to 0.10, 1 trial, 99 participants;   <a href="./references#CD006332-fig-0042" title="">Analysis 4.8</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>;  methylnaltrexone 0.30 mg/kg  MD ‐0.15, 95% CI ‐0.57 to 0.27, 1 trial 107 participants <a href="./references#CD006332-fig-0043" title="">Analysis 4.9</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). We judged the certainty of evidence for effect in short to medium term on opioid withdrawal symptoms to be low. We downgraded the certainty of evidence by one level for serious study limitations because of unclear risk of bias (reporting bias) and one for serious imprecision (data derived from fewer than 400 participants). </p> <p>Those in the methylnaltrexone 0.15 mg/kg arm experienced reduced pain intensity compared to placebo in the short term (at four‐hours following the intervention) (MD ‐0.20, 95% CI ‐1.02 to 0.62, 1 trial. 133 participants. <a href="./references#CD006332-fig-0044" title="">Analysis 4.10</a>. <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). There was little to no difference in pain intensity in the short term in those in the methylnaltrexone 0.3 mg/kg arm compared to placebo (MD ‐0.25, 95% CI ‐0.91 to 0.41, 1 trial, 152 participants. <a href="./references#CD006332-fig-0045" title="">Analysis 4.11</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). </p> <p>We judged the certainty of evidence for effect on pain intensity to be low. We downgraded the certainty of evidence by two levels, one for serious study limitations (unclear risk of bias due to reporting bias) and one for serious imprecision (data derived from fewer than 400 participants). </p> <p>Change in analgesic requirements was not reported.</p> </section> <section id="CD006332-sec-0103"> <h6 class="title">Serious adverse events</h6> <p>Two trials reported this outcome (364 participants) (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>;  <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). </p> <p>There were fewer serious adverse events in those in the methylnaltrexone arm than for those in the placebo arm (RR 0.59, 95% CI 0.38 to 0.93; I² = 0%; 2 trials, 364 participants. <a href="./references#CD006332-fig-0046" title="">Analysis 4.12</a>. <a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). In both trials, the investigators considered all serious adverse events as either not related or unlikely to be related to the trial drug. In <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>, the type of serious adverse events in the 11 participants who were receiving methylnaltrexone were: aneurysm ruptured, respiratory arrest, exacerbation of dyspnoea, suicidal ideation, aggression, malignant neoplasm progression, concomitant disease progression, myocardial ischaemia, aggravation of coronary artery disease, and aggravation of congestive heart failure. <a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a> did not describe the types of serious adverse events.  </p> <p>Althouh one trial did not report serious adverse events occurring during the randomised phase (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>),  during its open‐label phase three participants experienced such an event. One participant had flushing, one participant had delirium possibly related to methylnaltrexone, and one participant had severe diarrhoea and subsequent dehydration and cardiovascular collapse considered to be related to methylnaltrexone.  </p> <p>We judged the certainty of evidence for risk of a serious adverse event to be low. We downgraded the evidence by one level for study limitations (unclear risk of bias due to reporting bias) and one for serious imprecision (data derived from fewer than 400 participants). </p> </section> <section id="CD006332-sec-0104"> <h6 class="title">Number and type of adverse events</h6> <p>Three trials  reported this outcome (518 participants) (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). </p> <p>More participants in methylnaltrexone arms experienced adverse events than those in the placebo arms (RR 1.17, 95% CI 1.05 to 1.30; I² = 74% suggesting substantial heterogeneity between trials, 3 trials, 518 participants.  <a href="./references#CD006332-fig-0047" title="">Analysis 4.13</a>). We considered subgroup and sensitivity analyses to explore heterogeneity but none of the trials characteristics fulfilled any of our planned possible sources of heterogeneity. We judged the certainty of evidence for adverse events to be low. It was downgraded by two levels; one for study limitations (unclear risk of reporting bias) and one because of inconsistency due to substantial statistical heterogeneity between the trials. </p> <p>Adverse events were reported as severe, this was based on data from two trials (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). One reported that during the trial and open‐label phase that 19 participants had severe events that were possibly related to methylnaltrexone (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). In the other trial more participants in the placebo group experienced severe adverse events than in the intervention group (5/63 (8%) with methylnaltrexone versus 9/71 (13%) with placebo). The third trial did not report on severity (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>). </p> <p>All three trials reported that participants in both methylnaltrexone and placebo arms experienced abdominal pain, flatulence, nausea, and vomiting (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). There were more reports of abdominal pain in the methylnaltrexone arm compared to placebo (RR 2.18, 95% CI 1.50 to 3.18, I² = 65% suggesting substantial heterogeneity between trials, 3 trials, 667 participants.  <a href="./references#CD006332-fig-0048" title="">Analysis 4.14</a>). We did not undertake a sensitivity analyses as none of the trials characteristics fulfilled any of our planned possible sources of heterogeneity. There was little to no difference between the methylnaltrexone and placebo arms in the proportion who experienced flatulence (RR 1.88, 95% CI 0.99 to 3.57,  I² = 0%, 3 trials, 667 participants.  <a href="./references#CD006332-fig-0049" title="">Analysis 4.15</a>) or who experienced vomiting (RR 0.95, 95% CI 0.55 to 1.65,  I² = 0%, 3 trials, 667 participants. <a href="./references#CD006332-fig-0050" title="">Analysis 4.16</a>). There were more reports of nausea in the methylnaltrexone arm compared to placebo (RR 1.89, 95% CI 1.26 to 2.85, I² = 0%, 3 trials, 667 participants. <a href="./references#CD006332-fig-0051" title="">Analysis 4.17</a>). </p> </section> </section> <section id="CD006332-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD006332-sec-0106"> <h6 class="title">Number who dropped out due to adverse events </h6> <p>Two trials (364 participants) reported this outcome (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). There was little to no difference in the proportion of participants who dropped out of the study due to adverse events between the trial arms (RR 1.22, 95% CI 0.54 to 2.76, I² = 0%; 2 trials, 363 participants. <a href="./references#CD006332-fig-0052" title="">Analysis 4.18</a>). The other trial reported no dropouts occurred due to adverse events <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>. </p> </section> <section id="CD006332-sec-0107"> <h6 class="title">Use of rescue medication for laxation</h6> <p>Two trials (363 participants) reported this outcome (<a href="./references#CD006332-bbs2-0002" title="BullJ , WellmanCV , IsraelRJ , BarrettAC , PatersonC , ForbesWP . Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. Journal of Palliative Medicine.2015;18:593-600. ">Bull 2015</a>; <a href="./references#CD006332-bbs2-0010" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16) 2008. [CRSREF: 2866565]. ChamberlainBH , CrossK , WinstonJL , ThomasJ , WangW , SuC , et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management2009;38:683-90. ThomasJ , KarverS , CooneyGA , ChamberlainBH , WattCK , SlatkinNE , et al. Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine2008;358:2332-4. ">Thomas 2008</a>). Fewer in the methylnaltrexone arm needed for rescue medication for laxation compared to placebo (RR 0.67, 95% CI 0.49 to 0.91, I² = 0%; 2 trials, 363 participants. <a href="./references#CD006332-fig-0053" title="">Analysis 4.19</a>). </p> </section> <section id="CD006332-sec-0108"> <h6 class="title">Other secondary outcomes</h6> <p>Other measures of laxation responses and symptoms of constipation, satisfaction with bowel treatments, quality of life and participant preference were not reported. </p> </section> </section> </section> <section id="CD006332-sec-0109"> <h4 class="title">Low dose methylnaltrexone versus high dose methylnaltrexone</h4> <p>Two trials (518 participants) evaluated different dosing regimens of methylnaltrexone in people with advanced disease (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). One trial, irrespective of bodyweight, explored fixed doses of methylnaltrexone 1 mg, 5 mg, 12.5 mg, or 20 mg in 33 participants (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). Because of the limited number of participants in the trials, we provide outcomes for participants taking 1 mg compared to participants taking 5 mg or greater. The drug was administered on alternate days over one week. The other trial compared one dose of different dose‐ranging schedules of 0.15 mg/kg for 47 participants with 0.3 mg/kg for 55 participants (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). We did not combine the data because the dosing schedules differed. </p> <section id="CD006332-sec-0110"> <h5 class="title">Primary outcomes</h5> <p>See <a href="./full#CD006332-tbl-0006">summary of findings Table 6</a> for primary outcomes for methylnaltrexone 1 mg compared to methylnaltrexone 5 mg. </p> <section id="CD006332-sec-0111"> <h6 class="title">Laxation response</h6> <p>Two trials (135 participants) reported short‐term outcome. There was little to no difference in risk of spontaneous rescue‐free bowel movements within first 24 hours (at fours hours after first dose) between participants taking a lower dose to those on a higher dose (dose 1 mg compared to 5‐20 mg, RR 0.21, 95% CI 0.03 to 1.41, 1 trial, 33 participant.<a href="./references#CD006332-fig-0054" title="">Analysis 5.1</a>.<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; dose 0.15 mg/kg compared to 0.3 mg/kg, RR 1.06, 95% CI 0.77 to 1.46, 1 trial, 102 participants. <a href="./references#CD006332-fig-0054" title="">Analysis 5.1</a>. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). We judged the certainty of evidence for laxation response within 24 hours as low. We downgraded the certainty of evidence by one level for serious study limitations and one level for serious imprecision. This was because of unclear risk of bias (reporting bias) and fewer than 400 participants.  </p> <p>Only one trial (26 participants) reported outcomes in the medium term (after dosing at day three) (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). There was little to no difference in risk of spontaneous rescue‐free bowel movements between participants receiving 1 mg compared to participants receiving 5 mg or greater within four hours of dose on day three (day three: RR 2.91, 95% CI 0.82, 10.39; 1 trial, 26 participants. <a href="./references#CD006332-fig-0055" title="">Analysis 5.2</a>). We judged the certainty of evidence for laxation response at day three to be very low. We downgraded the certainty of evidence by one level for serious study limitations (unclear risk of reporting bias) and two for very serious imprecision (sparse data, 26 participants). Patient‐reported overall improvement in symptoms of constipation was not reported in the medium term.  </p> <p>Patient‐reported assessment of change in bowel status was reported in only one trial (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). There was little to no difference in improvement between dose arms at the end of the double‐blind phase (RR 0.98, 95% CI 0.71 to 1.35, 1 trial, 102 participants. <a href="./references#CD006332-fig-0056" title="">Analysis 5.3</a>). We judged the certainty of evidence for patient‐reported assessment of change in bowel status to be low. We downgraded the certainty of evidence by one level for serious study limitations and one level for serious imprecision. This was because of unclear risk of bias (reporting bias) and fewer than 400 participants.  </p> </section> <section id="CD006332-sec-0112"> <h6 class="title">Effect on analgesia</h6> <p>Two trials (135 participants) report on effect on analgesia in the short to medium term (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). There was little to no difference between trial arms in the mean change in symptoms of opioid withdrawal from baseline to four‐hour evaluation or medium term (MD ‐0.04, 95% CI ‐0.58 to 0.50, 1 trial, 102 participants. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>. <a href="./references#CD006332-fig-0057" title="">Analysis 5.4</a>; MD ‐0.25, 95% CI ‐0.84 to 0.34, 1 trial, 102 participants. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>. <a href="./references#CD006332-fig-0058" title="">Analysis 5.5</a>). In the other trial there was also little to no difference in the short term and medium term between trials arms in pain levels or symptoms of opioid withdrawal (data not provided) (33 participants) (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). </p> <p>Change in analgesic requirements was not reported.</p> <p>We judged the certainty of evidence for effect on analgesia to be low. We downgraded the certainty of evidence by one level for serious study limitations and one level for serious imprecision. This was because of unclear risk of bias (reporting bias) and fewer than 400 participants. </p> </section> <section id="CD006332-sec-0113"> <h6 class="title">Serious adverse events</h6> <p>Two trials (135 participants) reported on serious adverse events (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). In one trial, 15 participants experienced a serious adverse event (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). Which trial arm they were in was not reported. The events were lymphadenectomy, febrile neutropenia, depressed level of consciousness, suicide attempt, and delirium. All were considered unrelated to study drug. In the other trial, no serious adverse events occurred during the randomised trial phase, although during the open‐label phase three participants experienced such an event of which one had severe diarrhoea and subsequent dehydration and cardiovascular collapse (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). These were considered to be related to the study drug. We did not judge the certainty of evidence for serious adverse events as data were not complete. </p> </section> <section id="CD006332-sec-0114"> <h6 class="title">Number and type of adverse events </h6> <p>Two trials reported on adverse events (135 participants) (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). There was little to no difference in the occurrence of adverse events between the different dose arms in either study. We did not combine the study data as the dosing differed substantially per study (RR 1.00, 95% CI 1.00 to 1.00, 33 participants. <a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; RR 0.90, 95% CI 0.73 to 1.13, 102 participants. <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). The most common adverse event in both trials and per trial arm was abdominal pain. We judged the quality of certainty for adverse events to be low. This was because of serious study limitations due to unclear risk of bias (reporting bias) and imprecision (fewer than 400 participants). </p> </section> </section> <section id="CD006332-sec-0115"> <h5 class="title">Secondary outcomes</h5> <section id="CD006332-sec-0116"> <h6 class="title">Number who dropped out due to adverse events </h6> <p>Two trials reported on this outcome (135 participants) (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>; <a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). In one trial, one participant in methylnaltrexone 12.5 mg arm discontinued the trial because of an adverse event (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). This was an 84‐year‐old man who withdrew due to syncope. The event was transient and resolved without sequelae; the investigators assessed that it was related to the medication. This trial also reported that in the open‐label phase, after receiving three doses, a 20‐year‐old man was withdrawn from the trial due to abdominal cramping that was considered as probably related to the trial medication. In the other trial, none of the participants discontinued because of an adverse event (<a href="./references#CD006332-bbs2-0008" title="Assessment report for Relistor. Procedure No. EMEA/H/C/870. European Medicines Agency. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000870/WC500050566.pdf (accessed 1 April 2016). Center for Drug Evaluation and Research. Statistical review. Application 21-964. Food and Drug Administration. www.accessdata.fda.gov (assessed 01/04/16)2008. SlatkinN , ThomasJ , LipmanAG , WilsonG , BoatwrightML , WellmanC , et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology2009;7:39-46. ">Slatkin 2009</a>). </p> </section> <section id="CD006332-sec-0117"> <h6 class="title">Use of rescue medication for laxation</h6> <p>Only one trial (33 participants) reported this outcome (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). Those in methylnaltrexone 1 mg arm required a rescue laxative approximately twice as often as those in the higher dose groups of 5 mg, 12.5 mg, and 20 mg (data were not provided). </p> </section> <section id="CD006332-sec-0118"> <h6 class="title">Satisfaction with bowel movements</h6> <p>Only one trial (33 participants) reported this outcome (<a href="./references#CD006332-bbs2-0007" title="PortenoyRK , ThomasJ , Moehl BoatwrightML , GalassoFL , StamblerN , Von GuntenCF , et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study. Journal of Pain and Symptom Management2008;35:458-68. ">Portenoy 2008</a>). There was little to no difference in satisfaction with bowel movements between trials arms. Data were not provided. </p> </section> <section id="CD006332-sec-0119"> <h6 class="title">Other secondary outcomes </h6> <p>Other measures of laxation response in short to medium term and rescue‐free laxation response in the longer term, relief of other constipation‐associated symptoms, quality of life, preference were not reported. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006332-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006332-sec-0120"></div> <section id="CD006332-sec-0121"> <h3 class="title" id="CD006332-sec-0121">Summary of main results</h3> <p>This is an update of the review first published in 2008, and last updated in 2018. We sought to determine the effectiveness and safety of mu‐opioid antagonists (MOAs) for opioid‐induced bowel dysfunction (OIBD) in people with cancer and people receiving palliative care. Where reported (9/10) studies excluded patients in situations that may affect efficacy by compounding constipation such as any disease processes suggestive of abnormalities of the gastrointestinal tract, and chemotherapy. Five of the 10 randomised controlled trials (RCTs) included explored outcomes in cancer populations irrespective of disease stage. Two of these studies compared oral naldemedine with placebo, one of which also compared dosing regimens, and the other three compared oral prolonged‐released oxycodone/naloxone with oxycodone alone. Oral naloxone only compared with placebo was evaluated in people with advanced cancer. The other four trials compared subcutaneous methylnaltrexone either with placebo or different regimens of methylnaltrexone in palliative care populations, in which the majority of participants had advanced cancer. </p> <section id="CD006332-sec-0122"> <h4 class="title">Naldemedine compared with placebo in people with cancer</h4> <p>We found moderate‐certainty evidence that in the medium term (over two weeks) naldemedine may increase the risk of spontaneous laxations and the risk of adverse events. There was no clear evidence that it has little to no impact on opioid withdrawal symptoms or risk of serious adverse events. We found this evidence was of very low certainty on opioid withdrawal symptoms, and low for serious adverse events. Patient assessment of bowel status was not reported. </p> </section> <section id="CD006332-sec-0123"> <h4 class="title">Low‐dose naldemedine compared with higher‐dose naldemedine in people with cancer</h4> <p>The risk of spontaneous laxations in the medium term and risk of serious adverse events may be higher when naldemedine administered at 4 mg compared to 1 mg, but we found the evidence is of low certainty. There was little to no difference in doses in the impact on opioid withdrawal symptoms or risk of adverse events, but we found the evidence was of low certainty. Patient assessment of bowel status not reported. </p> </section> <section id="CD006332-sec-0124"> <h4 class="title">Naloxone compared with placebo in people with advanced cancer</h4> <p>There was no reported data on laxation response, patient assessment of bowel status, effect on analgesia, serious adverse events or adverse events. </p> </section> <section id="CD006332-sec-0125"> <h4 class="title">Naloxone with oxycodone versus oxycodone in people with cancer</h4> <p>Therewere no reported data on risk of spontaneous laxations. We found low‐certainty evidence which is inconsistent in whether naloxone with oxycodone compared to oxycodone only improves patients assessment of bowel status. There was little to no difference between naloxone with oxycodone compared to oxycodone on impact on opioid withdrawal symptoms or risk of adverse events, but we found the evidence was of low certainty. We found very low‐certainty evidence that naloxone with oxycodone has little to no impact on the risk of serious adverse events. </p> </section> <section id="CD006332-sec-0126"> <h4 class="title">Methylnaltrexone compared with placebo in people receiving palliative care</h4> <p>We found moderate‐certainty evidence that in the medium term methylnaltrexone may increase the risk of spontaneous laxations and low‐certainty evidence that it may improve patient assessment of bowel status. There was little to no difference between methylnaltrexone compared with placebo on impact on opioid withdrawal symptoms or that it increases the risk of a serious adverse event, but we found this evidence of low certainty. We found low‐certainty evidence that methylnaltrexone increases the risk of adverse events. </p> </section> <section id="CD006332-sec-0127"> <h4 class="title">Methylnaltrexone 1 mg compared with 5 mg or greater</h4> <p>We found low‐ to very low‐certainty evidence that there was little to no difference in impact between methylnaltrexone at 1 mg compared to 5 mg or greater on laxation response in the short and medium term. There was little to no difference on patient assessment of bowel status, opioid withdrawal symptoms, and adverse events but the evidence was of low certainty. Serious adverse events were underreported. </p> </section> </section> <section id="CD006332-sec-0128"> <h3 class="title" id="CD006332-sec-0128">Overall completeness and applicability of evidence</h3> <p>We sought trial evidence widely beyond published papers. Where available, we obtained regulatory documents; although these provided few new data. </p> <p>Our review findings were limited. The trials were few and this limited our combined analyses. In some analyses, there was statistical heterogeneity across the trials. In regards to the primary outcomes, this related to adverse effects of methylnaltrexone in comparison to placebo. We did not undertake sensitivity analyses as none of the trial characteristics fulfilled our criteria for possible sources of heterogeneity. The evidence on naldemedine was from two trials from the same research group. The trial on naloxone only measured one of our four primary outcomes of interest. </p> <p>The body of evidence could be argued as stronger for methylnaltrexone, as more evidence was provided on our primary outcomes of interest. It is important to reflect that this is overall of low‐certainty evidence, and in one of the four methylnaltrexone trials the assessment of impact of the drug may have been affected as participants in the placebo arm were on higher doses of opioids than those in the methylnaltrexone arm. Our analysis was more limited on methylnaltrexone dose response as we were unable to combine the studies because of different dosing schedules. </p> <p>Participant outcomes were under evaluated. Only two trials assessed quality of life (<a href="./references#CD006332-bbs2-0001" title="AhmedzaiSH , NauckF , Bar-SelaG , BosseB , LeyendeckerP , HoppM . A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine2012;26:50-60. Center for Drug Evaluation and Research, Medical Review. Application number: 205777Orig1s000. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf (accessed 17 November 2016). US Food and Drug Administration, Center for Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf (assessed 17 November 2016). ">Ahmedzai 2012</a>; <a href="./references#CD006332-bbs2-0005" title="KatakamiN , HaradaT , MurataT , ShinozakiK , TsutsumiM , YokotaT , et al. Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 2017;35:3859-66. KatakamiN , HaradaT , MurataT , ShinozakiK , Tsutsumi M, YokotaT , et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology 2018;29:1461-7. Report on the deliberation results: naldemedine tosilate. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https://www.pmda.go.jp/files/000222647.pdf (assessed 28/02/21) 20172017. ">Katakami 2017b</a>). Few trials reported on impact of MOAs on the intensity of pain. This may be as it is hard to assess formally as it is subjective, but it is an important to measure.  There are also other outcomes that were not measured in any of these trials that earlier research suggests need further exploration. This includes whether MOAs, in particular methylnaltrexone, increase cancer survival (<a href="./references#CD006332-bbs2-0049" title="JankuF , MossJ , KarpD , SingletonP , JohnsonL . Treatment with methylnaltrexone is associated with increased survival in patients with advanced refractory cancers treated for opioid induced constipation. European Journal of Cancer2015;51:S235.">Janku 2015</a>). </p> <p>We found, as we did in our previous update, no completed trials that fulfilled our inclusion criteria on naloxegol, which in 2014 was approved by the FDA for use in OIBD in people without cancer. However, there are trials of naloxegol that are registered as ongoing, the most recent is from 2017 (<a href="./references#CD006332-bbs2-0025" title="GuptaP . Naloxegol in treating patients with stage IIIB-IV non-small cell lung cancer. ClinicalTrials.gov2017. ">NCT03067708</a>). Evaluations on the development of new MOAs for OIBD, their effectiveness, and safety is an active research field. We found 11 trials in populations of people with cancer or people receiving palliative care (or both) that were in progress, awaiting assessment or were completed, but published results were not yet available at the time of publishing this review. </p> </section> <section id="CD006332-sec-0129"> <h3 class="title" id="CD006332-sec-0129">Quality of the evidence</h3> <p>None of the evidence for the primary outcomes was judged as high certainty. The certainty was mostly low or very‐low, commonly because of study limitations (because of attrition or reporting bias) alongside serious or very serious imprecision because data involved a limited or very limited number of participants/events. Some evidence, on spontaneous rescue‐free laxations and adverse events regarding naldemedine compared with placebo, was judged as moderate. It was down‐graded once because of serious risk of attrition bias. The only other outcome whose evidence was judged as moderate was spontaneous rescue‐free laxations in the medium term regarding methylnaltrexone compared with placebo; here it was downgraded because of unclear risk of reporting bias. In two instances where we were able to combine data another quality issue occurred; this was regarding inconsistency across trials because of substantial unexplained heterogeneity. This occurred in the comparison of methylnaltrexone with placebo for adverse advents and in comparison, of naloxone + oxycodone compared with oxycodone alone for serious adverse events. </p> </section> <section id="CD006332-sec-0130"> <h3 class="title" id="CD006332-sec-0130">Potential biases in the review process</h3> <p>We sought trial evidence widely, including five citation databases. We sought unpublished trial data from pharmaceutical and regulatory agencies databases. However, there are limited guidelines in how to seek unpublished data and searching regulatory agency websites is not straightforward. </p> <p>We limited inclusion to trials that specified that their participants had cancer, or were in palliative care, irrespective of disease stage. This is likely to have led to a loss of data, as trials we excluded may have included people with such characteristics, but the trial papers did not provide this level of detail. </p> <p>We included trials with methodological limitations. In addition, there is a potential problem due to carry‐over effects in the cross‐over designed trial (<a href="./references#CD006332-bbs2-0009" title="SykesNP . An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine1996;10:135-44. ">Sykes 1996</a>), and our combined analysis was limited by the number of trials available. As different MOA time points of greatest potential differ, in any future updates primary outcome time points may be need to be reconsidered and not standardised as in this update. </p> </section> <section id="CD006332-sec-0131"> <h3 class="title" id="CD006332-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>This is an update of a Cochrane systematic review examining the evidence for MOAs, as in its last version (<a href="./references#CD006332-bbs2-0077" title="CandyB , JonesL , VickerstaffV , LarkinPJ , StonesP . Mu-opioid antagonists for opioid induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD006332. [DOI: 10.1002/14651858.CD006332.pub3]">Candy 2018</a>) it is looking specifically for OIBD in cancer and palliative care populations. This update identified two new trials, whilst the certainty of the evidence for naldemedine has changed, the overall conclusions have not changed from the last published version. </p> <p>There are reviews that have evaluated the effect of MOAs for OIBD across different populations, although no recent Cochrane Review. One review identified 14 trials, in addition to four of the trials included in this review, they;included trials on methadone‐induced constipation and trials involving participants receiving an opioid for chronic non‐malignant pain (<a href="./references#CD006332-bbs2-0041" title="FordAC , BrennerDM , SchoenfeldPS . Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. American Journal of Gastroenterology2013;108:1566-74.">Ford 2013</a>). In their meta‐analysis of 14 trials of 4101 participants the authors found the MOAs methylnaltrexone, naloxone, and alvimopan were superior to placebo for the treatment of opioid‐induced constipation. However, the numbers of adverse events were significantly more common. In a more recent review in which the authors included trials of any treatments approved for opioid‐induced constipation; these included both MOAs and the laxatives lubiprostone and prucalopride (<a href="./references#CD006332-bbs2-0059" title="NeeJ , ZakariM , SugarmanMA , WhelanJ , HirschW , SultanS , et al. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clinical Gastroenterology Hepatology2018;16:1569-84.e2.">Nee 2018</a>). The authors identified 26 trials and came to similar conclusions on MOAs. In recognition of the heterogeneity they observed across the trials, to identify possible moderating factors they undertook sensitivity analysis and a meta‐regression. They found that treatments were more likely to be effective in study populations taking higher doses of opioids at baseline or refractory to laxatives. In this review our data is more limited preventing a repeat of their sensitivity analysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006332-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006332-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006332-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006332-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 1: Sponaneous rescue‐free bowel movements: Medium term" data-id="CD006332-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 1: Sponaneous rescue‐free bowel movements: Medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 2: Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg" data-id="CD006332-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 2: Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 3: Symptoms of opioid withdrawal: Medium term, naldemedine 0.2 mg" data-id="CD006332-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 3: Symptoms of opioid withdrawal: Medium term, naldemedine 0.2 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 4: Symptoms of opioid withdrawal: Medium term, naldemedine 0.4 mg" data-id="CD006332-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 4: Symptoms of opioid withdrawal: Medium term, naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 5: Serious adverse events" data-id="CD006332-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 5: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 6: Adverse events" data-id="CD006332-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 6: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 7: Proportion experiencing diarrhoea" data-id="CD006332-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 7: Proportion experiencing diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Naldemedine versus placebo, Outcome 8: Proportion who dropped out due to adverse events" data-id="CD006332-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Naldemedine versus placebo, Outcome 8: Proportion who dropped out due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 1: Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.1 mg versus 0.4mg" data-id="CD006332-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 1: Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.1 mg versus 0.4mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 2: Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.1 mg versus 0.2mg naldemedine" data-id="CD006332-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 2: Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.1 mg versus 0.2mg naldemedine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 3: Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.2 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 3: Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.2 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 4: Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 4: Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 5: Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg versus naldemedine 0.2 mg" data-id="CD006332-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 5: Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg versus naldemedine 0.2 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 6: Symptoms of opioid withdrawal: Medium term, naldemedine 0.2 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 6: Symptoms of opioid withdrawal: Medium term, naldemedine 0.2 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 7: Adverse events: naldemedine 0.1 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 7: Adverse events: naldemedine 0.1 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 8: Adverse events: naldemedine 0.1 mg versus naldemedine 0.2 mg" data-id="CD006332-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 8: Adverse events: naldemedine 0.1 mg versus naldemedine 0.2 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 9: Adverse events: naldemedine 0.2 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 9: Adverse events: naldemedine 0.2 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 10: Serious adverse events" data-id="CD006332-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 10: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 11: Diarrhoea: naldemedine 0.1 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 11: Diarrhoea: naldemedine 0.1 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 12: Diarrhoea: naldemedine 0.1 mg versus naldemedine 0.2 mg" data-id="CD006332-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 12: Diarrhoea: naldemedine 0.1 mg versus naldemedine 0.2 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 13: Diarrhoea: naldemedine 0.2 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 13: Diarrhoea: naldemedine 0.2 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 14: Proportion who dropped out due to adverse events: naldemedine 0.1 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 14: Proportion who dropped out due to adverse events: naldemedine 0.1 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 15: Proportion who dropped out due to adverse events: naldemedine 0.1 mg versus naldemedine 0.2 mg" data-id="CD006332-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 15: Proportion who dropped out due to adverse events: naldemedine 0.1 mg versus naldemedine 0.2 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Naldemedine dose, Outcome 16: Proportion who dropped out due to adverse events: naldemedine 0.2 mg versus naldemedine 0.4 mg" data-id="CD006332-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Naldemedine dose, Outcome 16: Proportion who dropped out due to adverse events: naldemedine 0.2 mg versus naldemedine 0.4 mg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 1: Symptoms of opioid withdrawal: medium term" data-id="CD006332-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 1: Symptoms of opioid withdrawal: medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 2: Serious adverse events" data-id="CD006332-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 3: Adverse events" data-id="CD006332-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 4: Nausea" data-id="CD006332-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 4: Nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 5: Proportion who dropped out due to adverse events" data-id="CD006332-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 5: Proportion who dropped out due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 6: Use of laxative rescue medication" data-id="CD006332-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 6: Use of laxative rescue medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 7: Quality of life" data-id="CD006332-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event, Outcome 7: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 1: Spontaneous rescue‐free bowel movements: short term" data-id="CD006332-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 1: Spontaneous rescue‐free bowel movements: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 2: Spontaneous rescue‐free bowel movements: medium term" data-id="CD006332-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 2: Spontaneous rescue‐free bowel movements: medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 3: Patient reported improvement in bowel status: medium term" data-id="CD006332-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 3: Patient reported improvement in bowel status: medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 4: Opioid withdrawal symptoms: short term" data-id="CD006332-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 4: Opioid withdrawal symptoms: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 5: Opioid withdrawal symptoms: mean change short term, lower dose (0.15 mg/kg) methylnaltrexone" data-id="CD006332-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 5: Opioid withdrawal symptoms: mean change short term, lower dose (0.15 mg/kg) methylnaltrexone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 6: Opioid withdrawal symptoms: mean change short term, higher dose (0.30 mg/kg) methylnaltrexone" data-id="CD006332-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 6: Opioid withdrawal symptoms: mean change short term, higher dose (0.30 mg/kg) methylnaltrexone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 7: Opioid withdrawal symptoms: medium term" data-id="CD006332-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 7: Opioid withdrawal symptoms: medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 8: Opioid withdrawal symptoms: mean change medium term, lower dose (0.15 mg/kg) methylnaltrexone" data-id="CD006332-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 8: Opioid withdrawal symptoms: mean change medium term, lower dose (0.15 mg/kg) methylnaltrexone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 9: Opioid withdrawal symptoms: mean change medium term, lower dose (0.3 mg/kg) methylnaltrexone" data-id="CD006332-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 9: Opioid withdrawal symptoms: mean change medium term, lower dose (0.3 mg/kg) methylnaltrexone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 10: Pain intensity: short term" data-id="CD006332-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 10: Pain intensity: short term</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 11: Pain intensity: Medium term" data-id="CD006332-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 11: Pain intensity: Medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 12: Serious adverse event" data-id="CD006332-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 12: Serious adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 13: Adverse events" data-id="CD006332-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 13: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 14: Abdominal pain" data-id="CD006332-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 14: Abdominal pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 15: Flatulence" data-id="CD006332-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 15: Flatulence</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 16: Vomiting" data-id="CD006332-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 16: Vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 17: Nausea" data-id="CD006332-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 17: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 18: Dropouts due to adverse event" data-id="CD006332-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 18: Dropouts due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-004.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Methylnaltrexone versus placebo, Outcome 19: Use of resuce medication" data-id="CD006332-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-004.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4: Methylnaltrexone versus placebo, Outcome 19: Use of resuce medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-004.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Methylnaltrexone dose, Outcome 1: Spontaneous rescue‐free bowel movements: short term" data-id="CD006332-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Methylnaltrexone dose, Outcome 1: Spontaneous rescue‐free bowel movements: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Methylnaltrexone dose, Outcome 2: Spontaneous rescue‐free bowel movements: medium term" data-id="CD006332-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Methylnaltrexone dose, Outcome 2: Spontaneous rescue‐free bowel movements: medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Methylnaltrexone dose, Outcome 3: Patient reported improvement in bowel status: short term" data-id="CD006332-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Methylnaltrexone dose, Outcome 3: Patient reported improvement in bowel status: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Methylnaltrexone dose, Outcome 4: Opioid withdrawal symptoms: short term" data-id="CD006332-fig-0057" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Methylnaltrexone dose, Outcome 4: Opioid withdrawal symptoms: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Methylnaltrexone dose, Outcome 5: Opioid withdrawal symptoms: medium term" data-id="CD006332-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Methylnaltrexone dose, Outcome 5: Opioid withdrawal symptoms: medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006332-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/urn:x-wiley:14651858:media:CD006332:CD006332-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Methylnaltrexone dose, Outcome 6: Adverse event" data-id="CD006332-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_t/tCD006332-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Methylnaltrexone dose, Outcome 6: Adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/media/CDSR/CD006332/image_n/nCD006332-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006332-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Naldemedine compared to placebo for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Naldemedine compared to placebo for opioid‐induced bowel dysfunction for people with cancer </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction </p> <p><b>Settings:</b> not stated </p> <p><b>Intervention:</b> naldemedine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Naldemedine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the short term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the medium term</b><sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>718 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.00</b> (1.59 to 2.52) <b>NNTB</b> 3 (3 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change in bowel status at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms of opioid withdrawal</b><sup>e</sup><b>in the</b> </p> <p><b>medium term</b><sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in opioid withdrawal was 0.0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in opioid withdrawal was 0.1 <b>lower</b> 0.1 mg; 0.3 <b>higher</b> 0.2 mg, 0.2 <b>higher</b> 0.4 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naldemedine 0.1 mg: <b>MD ‐0.10</b> (‐0.56 to 0.36); naldemedine  0.2 mg: <b>MD 0.30</b> (‐0.21 to 0.81); naldemedine  0.4 mg: <b>MD 0.20</b> (‐0.36 to 0.76)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 in comparison with naldemedine 0.1 mg and 0.4 mg, 114 in comparison with 0.2mg (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.34</b> (0.85 to 13.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>613 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> (1.19 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>RR:</b> risk ratio; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Defined in both trials as having 3 or more laxations (not induced by rescue medication) a week/who had an increase of one of more laxations (not induced by rescue medication) a week from baseline </p> <p><sup>b</sup> Within first 24 hours </p> <p><sup>c</sup> Over two weeks </p> <p><sup>d</sup> Downgraded by one level for serious study limitations because of high risk of attrition bias in one study </p> <p>e Measured by the Clinical Opioid Withdrawal Scale. Lower scores indicate symptoms of lower severity. Score of 5‐12 mild, 13‐24 moderate, 25‐36 moderately severe, more than 36 severe withdrawal. Maximum score 48.<br/><sup>f</sup> Downgraded by two levels for very serious study limitations because all of the data were derived from only one study with a high risk of attrition bias </p> <p><sup>g</sup> Downgraded by one level for serious imprecision as data were derived from fewer than 400 participants </p> <p><sup>h</sup> Serious non‐fatal events were reported, definition of what fits this criteria was not provided </p> <p><sup>i</sup> Downgraded by one level for serious imprecision due to wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Naldemedine compared to placebo for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006332-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Low dose naldemedine compared to higher doses for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Low dose naldemedine compared to higher‐dose for opioid‐induced bowel dysfunction for people with cancer </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction </p> <p><b>Setting:</b> not stated </p> <p><b>Intervention:</b> Naldemedine 0.1 mg daily </p> <p><b>Comparison:</b> Naldemedine 0.4 mg daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher dose</b> </p> <p><b>0.4 mg daily</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower dose</b> </p> <p><b>0.1 mg daily</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the short term</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the medium term<sup>b,c</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>821 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> (0.53 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change bowel status at end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms of opioid withdrawal</b><sup>f</sup><b>in the medium term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> <p>Mean change in opioid withdrawal</p> <p>0.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean change in opioid withdrawal <b>‐0.3 lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD </b> </p> <p><b>‐0.30</b> [‐0.85, 0.25] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0.2 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.25</b> (0.03, 2.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d.e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>786 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>660 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b> (0.67,1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; ; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Within first 24 hours following intervention and comparison treatment </p> <p><sup>b</sup> Defined in study as having 3 or more laxations (not induced by rescue medication) a week/who had an increase of one of more laxations (not induced by reduce medication) a week from baseline </p> <p><sup>c</sup> Measured over two weeks<br/><sup>d</sup> Downgraded by one level for serious study limitations due to unclear risk of bias (reporting bias) </p> <p><sup>e</sup> Downgraded by one level for serious imprecision (fewer than 400 participants for continuous data or fewer than 300 events for dichotomous data). </p> <p><sup>f</sup>Measured by the Clinical Opioid Withdrawal Scale. Lower scores indicate symptoms of lower severity. Score of 5‐12 mild, 13‐24 moderate, 25‐36 moderately severe, more than 36 severe withdrawal. Maximum score 48. </p> <p><sup>g</sup> Serious non‐fatal events were analysed, no further definition by study authors </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Low dose naldemedine compared to higher doses for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006332-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Naloxone compared with placebo for opioid‐induced bowel dysfunction in people with cancer and receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Naloxone compared with placebo for people with cancer and receiving palliative care with opioid‐induced bowel dysfunction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer and receiving palliative care with opioid‐induced bowel dysfunction </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> naloxone </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Naloxone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the short term</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the medium term<sup>b</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change in bowel status at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms of opioid withdrawal in the medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full data not provided </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Within first 24 hours </p> <p><sup>b</sup> Between 1 and 14 days </p> <p><sup>c </sup>Downgraded by one level for serious study limitations: unclear risk of bias (reporting bias)  </p> <p><sup>d </sup> Downgraded by two levels for very serious imprecision as sparse data (17 participants) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Naloxone compared with placebo for opioid‐induced bowel dysfunction in people with cancer and receiving palliative care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006332-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Naloxone + oxycodone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Naloxone + oxycodone prolonged release tablets compared with oxycodone prolonged‐released tablets for people with cancer and opioid‐induced bowel dysfunction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> naloxone + oxycodone prolonged‐release tablets (OXN PR) </p> <p><b>Comparison:</b> oxycodone prolonged‐released tablets (OXY PR) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oxycodone (OXY PR)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oxycodone + naloxone (OXN PR)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the short term</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>—</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements in the medium term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: Patient assessment of change in bowel status</b><sup>c</sup><b>at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>data not provided</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>data not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study 1: Mean change ‐ 11.14 (‐19.03, ‐3.24)</p> <p>Study 2: Little to no change p value = 0.264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Full data not provided in either study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms of opioid withdrawal</b><sup>f</sup><b>in the medium term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 7.27</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 0.63 <b>lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐0.63</b> (‐2.44, 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> (0.44 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d,e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>584 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01 </b>(0.87 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; ; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Within first 24 hours </p> <p><sup>b</sup> Between 1 and 14 days </p> <p><sup>c</sup> Measured in one study using 3‐item Bowel Function Index, where lower scores indicate better bowel function, and scores above 28.8 indicate constipation. Scores range from 0 to 100. In the other study change in bowel habits was measured using a 3‐point Likert Scale (worsened, no change, improved) </p> <p><sup>d</sup> Downgraded by one level because of serious study limitations (unclear risk of reporting bias)<br/><sup>e</sup> Downgraded by one level because of serious imprecision (data from fewer than 400 participants) </p> <p><sup>f</sup> Measured using the 16‐item Modified Subjective Opiate Withdrawal Scale. Lower scores indicate symptoms of lower severity. Range 0 to 64. Further scoring details not reported </p> <p><sup>g</sup> Not defined by trial authors </p> <p><sup>h </sup>Downgraded by one level because of serious unexplained inconsistency (substantial heterogeneity I<sup>2</sup> = 55%) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Naloxone + oxycodone prolonged release tablets compared with oxycodone prolonged‐released tablets for opioid‐induced bowel dysfunction in people with cancer irrespective of whether they were receiving palliative care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006332-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction </p> <p><b>Setting:</b> hospital and community </p> <p><b>Intervention:</b> methylnaltrexone </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with</b> </p> <p><b>methylnaltrexone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the short term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>701 per 1000 (625 to 770)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.97</b> (2.13 to 4.13) <b>NNTB 3</b> (2 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the medium term</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>671 per 1000<br/>(590 to 745) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.15</b> (4.76 to 13.95) <b>NNTB 2</b> (2 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laxation response: patient assessment of change in bowel status</b><sup>g</sup><b>at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>252 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>567 per 1000</p> <p>(488 to 644)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.32</b> (1.64 to 3.27)* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion reporting improvement</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms of opioid withdrawal</b><sup>h</sup><b>in the medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean 8.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean 0.2<b>lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐0.20</b> (‐0.80 to 0.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000<br/>(88 to 219) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> (0.38 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>797 per 1000<br/>(745 to 869) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b> </p> <p>(CI 1.05 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity was substantial (74%). We did not undertake a sensitivity analyses as none of our predefined criteria for undertaking one were matched. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>NNTB:</b> number needed to treat for an additional beneficial outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Measured by self‐report or clinician report </p> <p><sup>b</sup> Within first 24 hours following intervention and comparison treatment </p> <p><sup>c</sup>Downgraded once for serious study limitations because of unclear risk of reporting bias </p> <p><sup>d</sup>Downgraded once for serious imprecision (data fewer than 400 participants) </p> <p><sup>e</sup>Between 1 and 14 days </p> <p><sup>f</sup>As the effect size was large we did not downgrade for imprecision </p> <p><sup>g</sup>Measured in both studies using the Global Clinical Impression of Change, a scale ranging from 1 to 7, with higher scores indicating better bowel function </p> <p><sup>h</sup>Measured using the modified Himmelsbach Opioid Withdrawal Scale. Lower scores indicate symptoms of lower severity. Total scores range from 7 to 28.<br/><sup>i </sup>Not defined by trial authors </p> <p><sup>j</sup>Downgraded once for serious inconsistency because of substantial heterogeneity across trials </p> <p>*In one trial with 2 comparisons with the same control arm, we combined the intervention groups to form a single pairwise comparison </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Methylnaltrexone compared to placebo for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006332-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Methylnaltrexone lower dose compared to higher dose for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methylnaltrexone 1 mg compared to methylnaltrexone 5 mg or greater for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction </p> <p><b>Setting:</b> hospital and community </p> <p><b>Intervention 1:</b> lower‐dose methylnaltrexone (study 1: 3 doses, 1 week, 1 mg; study 2: 1 dose, 0.15 mg/kg) </p> <p><b>Intervention 2:</b> higher‐dose methylnaltrexone (study 1: 3 doses, 1 week, 5‐20 mg; study 2: 1 dose, 0.30 mg/kg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher dose (5 mg)?</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower dose (1 mg)?</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a</sup><b>in the short term</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: 609 per 1000</p> <p>Study 2: 639 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>499 per 1000</b> (250 to 100) </p> <p>Study 2: <b>681 per 1000</b> (515 to 904) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>RR 0.21</b> (0.03 to 1.41) </p> <p>Study 2: </p> <p><b>RR 1.06</b> (0.77 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 (2 studies) Study 1: n = 33</p> <p>Study 2: n = 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study data not combined as methylnaltrexone dosing differed substantially per study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: risk of spontaneous rescue‐free bowel movements</b><sup>a,</sup><b>in the medium term</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>647 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222<b>per 1000</b>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <b>RR 2.91</b> (0.82 to 10.39) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laxation response: patient assessment of change in bowel status</b><sup>g</sup><b>at the end of trial</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> (0.71 to 1.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms of opioid withdrawal in the medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>mean 0.25 <b>lower </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.25 (‐0.84 to 0.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not combined as methylnaltrexone dosing differed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In one trial, 15 serious adverse events occurred during the randomised trial phase but it does not report what arm the events occurred in.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: 1000 per 1000</p> <p>Study 2: 800 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>1000 per 1000</b> (1000 to 1000) </p> <p>Study 2: <b>723 per 1000</b> </p> <p>(580 to 902)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study 1: <b>RR 1.00</b> (1.00 to 1.00) </p> <p>Study 2: <b>RR 0.90</b> (0.73 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 (2 studies)</p> <p>Study 1: n = 33</p> <p>Study 2: n = 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,d</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study data not combined as methylnaltrexone dosing differed substantially per study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Measured by clinician or self‐report </p> <p><sup>b</sup> Within first 24 hours following intervention and comparison treatment </p> <p><sup>c</sup> Downgraded by one level for serious study limitations: unclear risk of bias (reporting bias) </p> <p><sup>d</sup> Downgraded by one level for serious imprecision as fewer than 400 participants. </p> <p><sup>e</sup>Between 1 and 14 days </p> <p><sup>f</sup> Downgraded by two levels for very serious imprecision as sparse data 26 participants and wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Methylnaltrexone lower dose compared to higher dose for opioid‐induced bowel dysfunction in people receiving palliative care irrespective of whether they had cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/full#CD006332-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006332-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Naldemedine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Sponaneous rescue‐free bowel movements: Medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.59, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.56, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Symptoms of opioid withdrawal: Medium term, naldemedine 0.2 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.21, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Symptoms of opioid withdrawal: Medium term, naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.36, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [0.85, 13.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.19, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Proportion experiencing diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.22, 2.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Proportion who dropped out due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.18 [1.28, 20.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Naldemedine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006332-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Naldemedine dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.1 mg versus 0.4mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.53, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.1 mg versus 0.2mg naldemedine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Spontaneous rescue‐free bowel movements: Medium term, naldemedine 0.2 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.85, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Symptoms of opioid withdrawal: Medium term, naldemedine 0.1 mg versus naldemedine 0.2 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.90, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Symptoms of opioid withdrawal: Medium term, naldemedine 0.2 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.49, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse events: naldemedine 0.1 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Adverse events: naldemedine 0.1 mg versus naldemedine 0.2 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse events: naldemedine 0.2 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Diarrhoea: naldemedine 0.1 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.40, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Diarrhoea: naldemedine 0.1 mg versus naldemedine 0.2 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Diarrhoea: naldemedine 0.2 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Proportion who dropped out due to adverse events: naldemedine 0.1 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Proportion who dropped out due to adverse events: naldemedine 0.1 mg versus naldemedine 0.2 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.33, 28.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Proportion who dropped out due to adverse events: naldemedine 0.2 mg versus naldemedine 0.4 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Naldemedine dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006332-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Symptoms of opioid withdrawal: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐2.44, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.87, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Proportion who dropped out due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.73, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Use of laxative rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.53, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.20, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Naloxone/oxycodone prolonged‐release tablets versus oxycodone prolonged‐release: adverse event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006332-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Methylnaltrexone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Spontaneous rescue‐free bowel movements: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [2.13, 4.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Spontaneous rescue‐free bowel movements: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.15 [4.76, 13.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Patient reported improvement in bowel status: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.64, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Opioid withdrawal symptoms: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.46, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Opioid withdrawal symptoms: mean change short term, lower dose (0.15 mg/kg) methylnaltrexone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.56, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Opioid withdrawal symptoms: mean change short term, higher dose (0.30 mg/kg) methylnaltrexone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.40, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Opioid withdrawal symptoms: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.80, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Opioid withdrawal symptoms: mean change medium term, lower dose (0.15 mg/kg) methylnaltrexone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.90, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Opioid withdrawal symptoms: mean change medium term, lower dose (0.3 mg/kg) methylnaltrexone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.57, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Pain intensity: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.02, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Pain intensity: Medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.05, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.50, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Flatulence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.99, 3.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.16 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.55, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.17 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.26, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.18 Dropouts due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.54, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.19 Use of resuce medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.49, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Methylnaltrexone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006332-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Methylnaltrexone dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Spontaneous rescue‐free bowel movements: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Spontaneous rescue‐free bowel movements: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.82, 10.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Patient reported improvement in bowel status: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.71, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Opioid withdrawal symptoms: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.58, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Opioid withdrawal symptoms: medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.84, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Methylnaltrexone dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006332.pub4/references#CD006332-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006332.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006332-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006332-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006332-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD006332-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006332-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006332-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006332-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006332\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006332\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006332\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006332\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006332\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006332.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006332.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006332.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006332.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006332.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714737465"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006332.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714737469"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006332.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d75fdeb20937d',t:'MTc0MDcxNDczNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 